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!!     ABSTRACT 
 
 
The occlusion of a cerebral artery or stroke often results in neuronal deficit 
and/or patient death. A partial recovery often follows non-fatal stroke and 
this may be due to the activation of the progenitor cells in the Sub-
Ventricular Zone (SVZ) naturally occurring after ischemia. In order to 
clarify the role of the SVZ neurogenesis in animal recovery, the effect of 
neurogenesis inhibition and boosting were studied in the mouse Middle 
Cerebral Artery occlusion model (MCAo). 6 to 10-week-old male mice 
were pre-treated with intracranial injections of lentiviral vector (LV) or 
integration deficient lentiviral vectors (IDLV), in order to target the SVZ. 
The IDLV carried an expression cassette encoding for a precursor Glial 
cell-derived neurotrophic factor (GDNF) or the tetanus toxin fragment C 
(TTC), which recently has been demonstrated to have growth factor like 
behaviour.  Another group of animals received the LV carrying a double 
promoter expression cassette encoding for an eGFP, and in order to inhibit 
the cell cycle in targeted cells the shRNA_Cyclin D1.  All vectors were 
co-injected with the LV_ pHR’SIN-cPPT-SEW, which contains an eGFP 
cassette. Two weeks later the animals received the MCAo, and for three 
weeks the sensorimotor behaviour was tested. Neurological assessment 
showed the sensory-motor debilitation was significant increased after the 
treatment with the LV_shRNA_CyclinD1 (* p<0.05); the IDLV_GDNF 
and IDLV_TTC groups showed a trend to improve neurological deficit in 
the subjects alive until day 5. In the IDLV_GDNF, the SVZ’s derived 
green cells were positively correlated with the ischemic volume, *p<0.05 
R=0.68, and the neurodegeneration, ***p<0.001 R=0.92. Moreover, while 
the SVZ neurogenesis inhibition reduced life expectancy, the boosting 
significantly improved it.  Immunofluorescence analysis showed a 
migration extended to the striatum and cortex with a max distance of 1.87 
mm from the SVZ. 
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BACKGROUND AND GENERAL INTRODUCTION 
 
1.1 GENERAL INTRODUCTION 
 
Every year in the UK 53,000 people die because of stroke, a major cause 
of mortality (9% of all total deaths). Stroke is also responsible for over 
9,500 premature deaths every year (data from the Stroke Foundation, 
published on http://www.scribd.com). 
 
Therapeutic treatments currently in use are very limited and only a small 
fraction of survivors is able to have a complete recovery. Recovery 
depends on the damage severity and only therapies based on rehabilitation 
seem to significantly improve patient conditions; in any case neuronal 
degeneration resulting from stroke, can be rescued by rehabilitation. 
Rehabilitation improves network functionality by enhancing plasticity in 
surviving neurons.  
 
Although a complete understanding of the disease’s outcome is not 
clarified yet, new strategies to improve patients’ conditions and to increase 
survivors are currently studied by numerous laboratories. On this view, the 
understanding of the brain’s ability to respond to ischemia could help 
development of new strategies, and could offer a significant contribution 
in the war against this disease.  
 
1.2 STROKE AND NEUROGENESIS 
 
Ischemic brain damage occurs in two different ways:  
• Ischemic stroke, occurring by an occlusion of a cerebral artery or stroke, 
that gives rise to neurodegeneration and/or neural damage, both in the 
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core1 region  and in surrounding penumbral2 areas  (Bederson, Pitts et al. 
1986) 
• Haemorrhagic stroke, occurring when a weakened blood vessels 
ruptures, causing a more localized and  reduced neuronal damage.  
 
There are several animal models that emulate some of the clinical features 
of stroke damage. One of the most common in use is the focal ischemia 
animal model by the occlusion (permanent or temporary) of the Middle 
Cerebral Artery (MCAo) (Figure 1.f1). The MCAo produces a reduction 
of cerebral blood flow within the striatum and the cerebral cortex, 
resulting in loss of cells. The damage depends on the duration of the 
occlusion; initial damage is localised in the striatum, while over 30 
minutes of occlusion can produce extensive damage across the brain 
(motor cortex, hippocampus and somatosensory cortex) (Menzies, Hoff et 
al. 1992; Traystman 2003; Adcock, Ford et al. 2006 Menzies, et al., 1992, 
Traystman, 2003). 
 
Numerous studies have reported that the MCAo produces an increase in 
proliferation of progenitors in the rodent Sub-Ventricular Zone (SVZ) and 
Sub-Granular Zone (SGZ). This was first described in 2001 (Jin, Minami 
et al. 2001) demonstrating an increase in the number of the Neural 
progenitor cells (NPCs) born in the SVZ and SGZ after ischemia3 (Jin, 
Minami et al. 2001; Zhang, Zhang et al. 2001; Arvidsson, Collin et al. 
2002; Parent, Vexler et al. 2002). 
In an experiment performed by Parent et al. (2002), the increase in the 
number of NPCs was detected as the increase of the BrdU labelled cells in 
the perinfarct regions ten days after MCAo (Parent, Vexler et al. 2002). 
                                                
1 The core region is where the highest damage occurs due to neurodegeneration resulting in a 75-
90% reduction in blood flow. 
2 The penumbra area is the area surrounding the core, where neurodegeneration is reduced but 
cellular damage is still significant. 
3 Ischemia, the reduction of blood supply responsible for neurodegeneration and severe cellular 
damage, is synonymous with stroke 
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Moreover, Thirty-five days after MCAo, many of the “new born cells” 
expressed DARPP-32 or Calbindin4  (Arvidsson, Collin et al. 2002; Parent, 
Vexler et al. 2002).  
Gu et al. in 2000 administrated the cell proliferation marker 5-
bromodeoxyuridine (BrdU) to Wistar rats, which thereafter underwent 
MCAo. The immunofluorescence proved a majority of glia, microglia and 
endothelial cells labelled with the BrdU, moreover 3% to 6% of this cells 
expressed the neuronal specific marker Map-2.  These cells were randomly 
distributed on the neocortical layer II and IV (Gu, Brannstrom et al. 2000). 
Many laboratories in analogue projects confirm these studies (Zhang, 
Zhang et al. 2001; Arvidsson, Collin et al. 2002; Parent, Vexler et al. 
2002; Gotts and Chesselet 2005). Concordant with our observations, these 
data demonstrated that the multiplication of progenitors is naturally 
stimulated by neurodegeneration. 
 
Besides, 18 days after MCAo Yamashita and colleagues were able to 
detect, 98% of progenitors in the striatum (n = 1108 cells) and they were 
co-expressing Dcx and βIII-tubulin5 (Yamashita, Ninomiya et al. 2006).  
In the experiment reported by Yamashita et al. (2006) the post ischemic 
detection of NPCs was obtained by an Ax-CAN-Cre plasmid injection into 
the lateral ventricle of CAG-CAT-Cre transgenic mice. This technique 
allowed long lasting expression and detection of eGFP in NPCs migrated 
from the SVZ to the ischemic regions. The analysis after death 
demonstrated a 29% (n = 5 cells) of eGFP-positive cells co-expressing 
NeuN (Yamashita, Ninomiya et al. 2006). Immunoelectron microscopy 
proved that the eGFP-positive axons contained presynaptic vesicles and 
formed synapses with the neurons located in the surrounding area 
(Yamashita, Ninomiya et al. 2006).  
 
                                                
4 DARPP-32 and calbindin are Medium-sized spiny neuronal markers 
5  Neuronal  marker 
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More recently Ohira et al. (2010) reported a new neurogenic area in rat 
neocortical layer one which is activated after ischemia (Ohira, Furuta et 
al.; Ohira, Furuta et al. 2010).  
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           Figure 1.f1  Middle cerebral artery occlusion. 
a) Map of the regions that receive blood supply delivered by the Middle Cerebral Artery, 
recognizable by the yellow areas,Sinauer Associates, 2002. b) C57/Bl/6, six week-old 
male, received 1 h MCAo and two weeks later was killed by transcardial perfusion; the 
staining was performed by Haematoxylin and Eosin. 
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1.2.1 NEUROGENESIS IN RODENT BRAIN   
 
NPCs are self-renewing, multipotent cells able to differentiate into 
ependymal cells, neurons, astrocytes and oligodendrocytes (Taupin and 
Gage 2002). The existence of active or quiescent NPCs in the adult 
mammalian nervous system was demonstrated within the neocortical layer 
one, SGZ and SVZ (Ohira, Furuta et al.; Altman and Das 1965; Corotto, 
Henegar et al. 1993; Luskin 1993). In physiological conditions activation 
of NPC divisions in the SVZ produces new-born cells able to migrate 
through the Rostral Migratory Stream (RMS), reaching the Olfactory 
Bulbs (OBs). Toward the migratory pathway and in the OBs, migrating 
neuroblasts differentiate in interneurons, glomerular and periglomerular 
cells (Figure 1.f2 and 1.1.f3) (Doetsch, Garcia-Verdugo et al. 1997).  
 
In some circumstances, for example after stroke, NPCs deviate from their 
“physiological pathway” and migrate toward the damage regions (Gotts 
and Chesselet, 2005). Once they reach the ischemic areas, NPCs associate 
with reactive astrocyte and blood vessels to produce neurovascular niche 
like structures (Ohab, Fleming et al. 2006; Thored, Arvidsson et al. 2006; 
Yamashita, Ninomiya et al. 2006). 
 
The NPCs dissected from SVZ can be cultured in vitro with the use of 
mitogens (EGF or FGF2), and they grow as free-floating spheres 
(neurospheres). Upon mitogens removal, neurospheres can differentiate 
into adult neurons, astrocytes or oligodendrocytes (Lennington, Yang et al. 
2003). 
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Figure 1.f2. Sub-Ventricular Zone (SVZ) (Taupin and Gage, 2002).  
 
The SVZ is a neurogenetic area located on the wall of the third cerebral ventricle. NSCs 
here are maintained in a quiescent state until appropriate stimuli occur to affect their 
division, migration and differentiation.  
 
 
 
Figure 1.f.3. Rostroal-mygratory stream and SVZ (Taupin and Gage, 
2002) 
The picture shows a sagittal section of a rodent brain; highlighted the SVZ 
from which the neuroblasts migrate toward the OBs. The neuroblasts 
travel in a chain-like structure that transient on a specialized route called 
RMS; the route terminates at OBs level. 
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1.2.2 REGULATION AND MAINTENANCE OF THE 
BRAIN NEUROGENIC AREAS: THE GROWTH FACTORS 
FAMILY 
 
The Nerve Growth Factor (NGF) was discovered in the late forty by Rita 
Levi Montalcini and Stanley Cohen; since then, the interest for this 
compound and its big family had seen an increasing attention and wide 
therapeutics application (Orts Llorca 1988; Hamburger 1993; Aloe 2004). 
The NGF comprises a big family of proteins that are involved in neuronal 
survival as well as stimulate dendritic branching and plasticity. In the 
Nervous System (NS) the Growth Factor (GF) family is highly expressed 
during development, as well as in the adult is an important factor for 
neuronal survival and plasticity (Pardon 2010). The GF family is currently 
applied in brain research with particular interest for the regulation and 
survival of NPCs. 
 
1.2.2.1 EGF AND FGF2 
 
Self-renewal and long-term survival of NPCs is stable when maintained in 
culture by two well known GF: the Epidermal Growth Factor (EGF), and 
Fibroblast Growth Factor 2 (FGF2) (Reynolds and Weiss 1992; Kuhn, 
Winkler et al. 1997). Some studies investigating the effects of EGF and 
FGF2 on telencephalon development, have demonstrated the closely 
regulated control of such molecules: FGF2 is produced early and during E 
8.56, whilst EGF is expressed only at E14.47 (Tropepe, Sibilia et al. 1999; 
Maric, Maric et al. 2003). In the adult NS SVZ’s NPCs express both EGF 
receptor and the FGF receptor 1, and hence respond to either EGF or 
FGF2 (Gritti, Frolichsthal-Schoeller et al. 1999). 
1.2.2.2 IGF-1 
 
                                                
6  Embryonic day 8,5.  
7  Embryonic 14,4. Between eighteenth and nineteenth days of embryo life time 
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Yan et al. (2006) demonstrated that Insulin Growth Factor 1 (IGF1) is 
produced by astrocytes in the rat penumbral cortex. This is one of the post-
ischemic up-regulated diffusible factors detectable after focal ischemia, 
and acts to promote progenitor cell proliferation. Interestingly, no IGF-1 
positive cells were observed in the post-ischemic dentate gyrus (DG) and 
SVZ (Yan, Sailor et al. 2006). IGF-1 is an endogenous mitogen which acts 
widely during development including in neurogenic areas. The action of 
IGF-1 is closely related to the concomitant occurrence of mitogens like 
EGF or FGF-2, and promotes differentiation after its withdrawal (Kalluri, 
Vemuganti et al. 2007). 
 
1.2.2.3 CYCLIN D1 
 
Cell cycle activation is strictly regulated by a number of factors known as 
cyclins. Cyclin D1 is a limiting molecule that promotes the progression 
from G1 to S phases of mitosis. Many factors controls Cyclin D1 gene 
transcription; for example, the interaction of many growth factors like 
EGF with the specific membrane receptor, can induce activation of the 
ERK and PI3/Akt pathways, in turn responsible to increase Cyclin D1 
transcription and the protein accumulation in the cytoplasmic region 
(Burch and Heintz 2005). The cytoplasmic accumulation of Cyclin D1 
leads to Cdk4 association, in turn responsible for the complex activation.  
As kinase-complex, it starts to interact with different cellular pathways by 
protein phosphorylation; for instance, the phosphorylation of the 
Retinoblastoma protein (Rb) determines the reduction of affinity with the 
E2F and in turn this is responsible for the cell cycle progression (Burch 
and Heintz 2005). Rb is a repressor factor that binds8 the Transcription 
Factor Element 2 (E2F). The kinase activity of CyclinD1/Cdk4 complex 
phosphorylates Rb/E2F, which is in turn responsible for the release of Rb 
                                                
8             E2F is able to activate many genes involve in S phase progression, particularly cyclin E 
gene 
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and E2F activation (Dowdy, Hinds et al. 1993; Ewen, Sluss et al. 1993) 
(Figure 1.f4).    
When the cell cycle is blocked in G1, the E2F is inactive by the binding to 
the Rb protein. In these circumstances, Rb recruits the histone deacetylase 
(HDAC) and methyltransferase (HMT) making the DNA inaccessible for 
E2F (Brehm, Miska et al. 1998; Luo, Postigo et al. 1998; Magnaghi-Jaulin, 
Groisman et al. 1998; Nielsen, Schneider et al. 2001). At DNA level, the 
modification of histone tails by HDAC and HMT, causes them a variation 
in charge by deacetylation and methylation of its lysine and arginine 
aminoacids. This results in an alteration of chromatin structure, and is in 
turn responsible for gene silencing (Figure 1.f5). The close association 
between the histone complex and DNA prevents any access for enzymes 
and factors necessary for transcription (Figure 1.f5) (Coqueret 2002). 
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Figure 1.f4. Cyclin D1 pathway.  
 
Extracellular stimuli, such the binding of growth factors (GF) to the receptor can increase 
the amount of the cytoplasmic Cyclin D1, which becomes active by interaction with 
Cdk4. As a complex CyclinD1-cdk4 migrates in the nucleus where the Kinase activity of 
CDK4 phosphorylate the Rb-E2F complex and is responsible for the release of the 
transcription factor E2F. E2F as last is involved in DNA ultra-structure modifications and 
S-phase genes activation.  
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Figure 1.f5. Chromatin remodelling by HDACs, HATs and histone 
methylase (Adcock, Ford et al. 2006).  
 
Chromatin remodelling systems: histone acetyltransferase complex (HAT) adds the acetyl 
group to the histone tails; this modification reduces DNA condensation, thus increasing 
enzyme accessibility. The inverse action is performed by HDAC for a reduced DNA 
accessibility and gene silencing. The methylation by HMT often follows deacetylation 
creating a stronger gene silencing.   
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1.2.2.4 GDNF 
 
The glial cell-line derived growth factor (GDNF), acting through the 
glycosylphosphatidylinositol- (GPI) receptor c-Ret, a transmembrane 
tyrosine kinase receptor, and the glial cell line-derived neurotrophic factor 
family receptor α 1, 2, 3 and 4, GFR α1, α2, α3 and α4, is able to promote 
cell survival and in vitro neuron differentiation. Moreover, it was 
demonstrated that GFR α1 mRNA is up-regulated in SVZ and Cortex after 
2 hours MCAo (Figure 1.f6) (Arvidsson, Kokaia et al. 2001).  
 
Stroke induces widespread changes in gene expression for glial cell line-
derived neurotrophic factor family receptors in the adult rat brain. 
Dempsey et al. (2003) proved a direct effect of GDNF on SVZ expansion. 
Prior to the ischemia being induced by MCAo, the animals were subjected 
to 24 hours intracerebroventricular infusion of GDNF, and one week after 
a significant increase in NPCs was noted in the SVZ (Dempsey and 
Kalluri 2007). The newly-formed NPCs survived for three weeks post 
MCAo (Dempsey, Sailor et al. 2003). 
 
 
 
 
 
Figure 1.f6. Stroke induces up regulation of GFR α1 receptor (Arvidsson, 
Kokaia et al. 2001).  
 
Effect of 2h_MCAo and 24h of reperfusion in a rat brain: the ischemia increased GFR α1 
mRNA in the SVZ and Cortex. 
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1.2.2.5 TTC 
 
The tetanus toxin is a neurotoxin secreted from the Clostridium tetani 
bacteria. The toxin comprises two polypeptide chains connected by a 
disulfide bond. The heavy chain can be divided into two different regions: 
the binding domain and the translocation domain. The binding domain is 
able to bind the gangliosides onto the nerve terminals and to be up taken 
by neurons. The neurotoxin, once in neurons, can be transported along the 
axon and across synapses and it can act at several sites within the Central 
Nervous System (CNS) and sympathetic NS. The translocation domain 
allows the neurotoxin to access cytosol. The light chain is a zinc 
endopeptidase that once activated by cytoplasmic enzymes, is able to cut 
the disulphide bond between the two chains. Moreover, it cuts 
Synaptobrevin 2 and determines the block of the release of GABA and 
Glycine to motor neurons, in turn causing the persistent muscle contraction 
symptomatic of tetanus (Roux, Saint Cloment et al. 2005; Caleo and 
Schiavo 2009). 
The tetanus toxin fragment C (TTC) is the C terminal portion of the heavy 
chain that is considered non-toxic, and in research is used as a neuronal 
tract tracer.  
 
Many studies have demonstrated the effect of TTC on improving 
compound delivery, such as that of mature GDNF in the CNS to provide 
neuro-protection to axotomized motor neurons (Larsen, Benn et al. 2006). 
Moreover, its neurotrophic-like effect was quite recently demonstrated in 
the ALS mouse model. In this experiment conducted by Moreno-Igoa et al. 
in 2009, naked DNA encoding for the TTC was intramuscularly injected in 
the transgenic SOD1G93A mouse model; the treatment improved hindlimb 
muscle innervation, delayed the ALS onset through improved motor 
neuron survival, and mediated lifespan elongation (Moreno-Igoa, Calvo et 
al. 2010). 
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1.2.3 INCREASE OF GROWTH FACTOR PRODUCTION 
AFTER ISCHEMIA 
 
After ischemia many growth factors and related receptors are up-regulated 
within the damaged tissue (Lippoldt, Reichel et al. 2005). Some published 
studies pointed out possible relationships between post MCAo 
neurogenesis and growth factors (Dempsey and Kalluri 2007). The action 
of these stimulating factors is not always closely related to the 
proliferation of neural progenitors, some of which can induce mitosis, like 
EGF and FGF2, while others block cell self-renewal. Transforming 
Growth Factor β1 (TGFβ1) is an example of a factor which blocks self-
renewal; its action directly interrupts cell division through up-regulation of 
mitosis inhibitors (Yamashita, Ninomiya et al. 2006). 
 
1.3 NEUROGENIC ENVIRONMENT 
1.3.1 THE NICHES 
 
Stem cells are distinguished from other cell types by two specific 
characteristics: they can generate identical daughter cells from division or 
self-renewal and they can produce different cell types after differentiation. 
In order to control and regulate self-renewal and multipotency, the specific 
environment of the neuronal niche is required. This niche provides 
paracrine and autocrine signals, in turn responsible for stem cell activation, 
differentiation and finally, niche support cells. Within the neuronal niche, 
stem cells are anchored to the basal lamina or stromal cells; the 
organization of this micro-environment provides a specific substrate which 
is pivotal to cells’ orientation and division, and to modulate regulatory 
factors and metabolites accessibility (Riquelme, Drapeau et al. 2008; 
Imayoshi, Sakamoto et al. 2009; Ming and Song 2011; Yao, Mu et al. 
2012). 
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1.3.2 NEUROGENIC AREAS 
 
1.3.2.1 SVZ IN PHYSIOLOGICAL AND PATHOLOGICAL 
CONDITIONS  
 
The SVZ is located along the lateral wall of the third ventricle, and 
consists of a layer of quiescent cells separated from cerebrospinal fluid 
(CSF) by multi-ciliate ependymal cells. The newly-born cells originate 
from the SVZ migrate in a chain-like structure toward the RMS pathway 
by which they reach the OBs. Within the OBs the newly-formed inhibitory 
interneurons, granules and periglomerular cells are integrated into the 
neuronal network (Belluzzi, Benedusi et al. 2003).  
 
In pathological conditions, for example, post MCAo, SVZ progenitors 
respond to the damage through reactivation of the cell cycle and migration 
toward the ischemic areas (Wurmser, Palmer et al. 2004). The migration 
occurs via chain like structures closely associated with endothelial cells. 
Once they reach the ischemic area, they associate with astrocytes and 
express Dcx (Yamashita, Ninomiya et al. 2006). This cluster organization 
resembles the neuronal niches located in the neurogenic areas (Louissaint, 
Rao et al. 2002; Alvarez-Buylla and Lim 2004; Wurmser, Palmer et al. 
2004; Yamashita, Ninomiya et al. 2006). Migrating neuroblasts use 
chemoattractant molecules to reach the infarct area. Stromal Derived 
Growth Factor (SDF-1) and Angioprotein 1 (Ang-1) are proteins secreted 
by endothelial cells and are up-regulated in hypoxic conditions. These 
proteins regulate stem cell differentiation and migration through the 
receptors Tie2 and CXCR4 (Ohab, Fleming et al. 2006). Angiogenesis is 
associated with neurogenesis in the niche environment (Leventhal, Rafii et 
al. 1999; Alvarez-Buylla and Lim 2004; Wurmser, Palmer et al. 2004). 
Moreover Ohab et al. (2006) demonstrated a functional link between the 
formation of new blood vessels and neuroblast migration occurring post 
MCAo. In this study they inhibited angiogenesis via endostatin treatment, 
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and demonstrated a 10-fold Dcx-positive cell reduction in the perinfarct 
area (Ohab, Fleming et al. 2006). 
1.3.2.2 SGZ IN PHYSIOLOGICAL AND PATHOLOGICAL 
CONDITIONS 
 
The SGZ is located within the hippocampus, between the granule cell 
layer of the dentate gyrus (DG) and the hilus. This neurogenic area has 
been demonstrated to be present in mammals, especially in superior 
primate brain. The granular zone forms relatively late during development 
(around one week before birth) and produces neurons over the whole 
lifetime. Numerous factors regulate the SGZ. For instance, the SGZ is 
negatively regulated by age and stress hormones (corticosterone and 
cortisol), and positively regulated by estrogen, progesterone and 
antidepressants (Galea, Spritzer et al. 2006; Brinton, Thompson et al. 
2008; Schoenfeld and Gould 2012)  
 
The SGZ produces and integrates in the hippocampus circuit around ten 
thousand newborn neurons in a life time. The hippocampus is a limbic 
structure involved in learning and memory. Learning increases 
neurogenesis in SGZ and promotes survival of newly generated cells 
(Gould, Beylin et al. 1999). Once new NPCs have been generated, they 
migrate for a short distance in the granular layer, extending dendrites to 
the molecular layer and starting to pull out the growth cone along the 
mossy fibre path. These cells are completely able to be reinserted into the 
neuronal network and to become actively functional.  
The SGZ seems to have at least two different astrocyte populations: radial 
and horizontal astrocytes. The radial astrocytes express Nestin and extend 
basal processes into the granule cell layer. The horizontal astrocytes which 
are in turn generated by the radial astrocytes do not express nestin and 
express S100; they extend basal processes under the granule cell layer 
(Riquelme, Drapeau et al. 2008). 
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Although SGZ and SVZ are well established areas of neurogenesis in 
many animal models, in humans the notion of existence of an SVZ-like 
region is still controversial (Curtis, Kam et al. 2007; Sanai, Berger et al. 
2007).  
 
1.4 LENTIVIRAL VECTORS 
 
1.4.1 BRIEF HISTORY AND GENERAL BACKGROUND 
 
The idea of using viral vectors to deliver genes into eukaryotes was first 
conceived in the late 1970s, from the meeting of molecular virology and 
the first characterization studies of genetic diseases with Mendelian 
inheritance. Among the multiple types of viral vectors available, lentiviral 
vectors have relatively high coding capacity (around 7.5 kb), low 
immunogenicity and the ability to transduce non-dividing cells. The most 
commonly used lentiviral vectors are derived from HIV-1 (Cockrell and 
Kafri 2003; Cockrell and Kafri 2007). 
 
In 1991 and 1992 the ability of the Human Immunodeficiency Virus type 
1(HIV-1) to infect non-dividing macrophages and non-proliferating cells 
was demonstrated in vitro (Weinberg, Matthews et al. 1991; Lewis, Hensel 
et al. 1992). The aptitude to infect non-dividing cells depends on the 
preintegration complex (PIC). This complex contains diverse viral proteins 
(Viral protein r, Vpr; Viral matrix protein; integrase), some host proteins 
(including the Barrier-to-autointegration factor) and the viral dsDNA or 
provirus. The main role of the complex is to mediate the active transport of 
the dsDNA through the nuclear pores, and to allow the integration into the 
host chromatin (Fouchier and Malim 1999). The integrase is the protein 
responsible for the viral DNA integration and, as discussed below, a single 
substitution in its amino acid chain sequence can reduce or prevent the 
catalytic activity. In this case, the non-integrated vector DNA can remain 
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in an episomal state, and be efficiently transcribed, particularly in 
quiescent cells (Yanez-Munoz, Balaggan et al. 2006). 
 
The initial lentiviral vectors produced did not have a wide tropism, but 
were limited to transduction of CD4-producing target cells, and with high 
probability of producing replication competent particles (Poznansky, 
Lever et al. 1991; Buchschacher and Panganiban 1992). A real 
improvement followed the introduction of pseudotyping, by which the wt 
HIV envelope protein is substituted with that from other virus having 
wider tropism, particularly the Vesicular Stomatitis Virus envelope 
glycoprotein G (VSV-G). Crucial was also the introduction of new 
strategies to reduce the likelihood of recombination events between vector 
components (Naldini, Blomer et al. 1996). These pseudotyped LV were 
able to efficiently transduce human cells in culture and rat neurons in vivo 
(Naldini, Blomer et al. 1996; Naldini, Blomer et al. 1996). 
 
The most important limitation of these first viral systems was the 
biosafety: the probability to produce replication-competent elements in the 
host organism was a big obstacle for possible therapeutic applications. 
From 1997 many genes involved in the viral replication were eliminated, 
and the viral genome was first split into 3 different plasmids (second 
generation LV) then into four (third generation LV) (Sakuma, Barry et al. 
2012). This not just reduced the probability of recombination between viral 
vector plasmids, improving the biosafety, but also increased vector genes 
delivering capability. In order increased  biosafety, LVs were developed 
from non-primate Lentiviruses (Naldini 1998). 
 
 
1.4.2 HIV LIFE CYCLE  
 
The human immunodeficiency virus (HIV) is the virus responsible for the 
Acquired Immune Deficiency Syndrome (AIDS) (Janssen, St Louis et al. 
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1992; Maeda and Mitsuya 2007; Sullivan, Patel et al. 2011; Owen 2012). 
HIVs belong to the lentivirus genus, within the retrovirus family. 
Lentiviruses are complex retroviruses which in addition to gag, pol and 
env contain accessory genes. The HIV life cycle can be divided into early 
and late stages. The early stage starts with the interaction of the viral 
envelope protein gp120 with the macrophages receptor CD4, also located 
on the surface of T-helper lymphocytes; both of them are important cells 
of the immune system. After the first interaction between pg120 and CD4, 
a third protein; the trans-membrane chemokine receptor CCR5 is recruited. 
The co-receptor CCR5, together with the CD4, determines the site where 
the viral envelope fuses with the host cellular membrane and the viral 
nucleocapsid accesses the cytoplasm. After the macrophages infection, a 
pg120 modified protein is expressed on the cellular membrane, in turn 
responsible for the interaction with a different receptor located on the T-
cells membrane, the CXCR4 (Nguyen and Taub 2002). The result of this 
infection is a severe reduction of both macrophages and T-cells, in turn 
responsible for the development of AIDS (Figure 1.f7). 
 
The viral genome consists of ~9-kb RNA encoding for 15 different 
proteins (Table 1.1.t1) (Frankel and Young 1998). Once in the host 
cytoplasm the viral nucleocapsid is disassembled (uncoating), and a pre-
integration complex (PIC) is formed. Once built, the PICs are able to 
mediate the nuclear transport and the provirus integration (Figure 1.f7) 
(Nisole and Saib 2004). 
 
The late stage begins when the double strand cDNA is integrated into the 
host genome, and gene transcription starts. The first transcripts to be 
translated are Tat, Rev and Nef: Tat controls the rate the proviral 
transcription is activated, Rev is involved in the proviral mRNA splicing 
before the nuclear export, while, Nef is responsible for the particles 
released by endocytosis. The proviral mRNA is retained in the nucleus 
until it is spliced as an effect of the Rev binding to the RRE. The nuclear 
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accumulation of Rev determines the shift between highly spliced mRNA, 
single spliced and un-spliced, and it is responsible for the viral life cycle 
phases. The structural proteins are produced by the Gag and Env 
transcripts, and the viral genome packed into the capsid. The capsid is 
built by a protein-protein interaction of the Gag and Pol polyproteins with 
the Capsid protein (CA). The ssRNA is packed into the capsid as a result 
of the interaction between the Ψ sequences and the NC protein. 
Additionally, the package contains Vif, Vpr, Nef and some cellular tRNA 
(Figure 1.f7) (Frankel and Young 1998; Nielsen, Pedersen et al. 2005). 
 
Budding of the nucleocapsid complex through the plasma membrane 
produces the envelope coating; the envelope in turn contains the 
extracellular gp120 and transmembrane protein gp41, both necessary to 
start the successive interaction with T-helper and macrophages cells 
(Figure 1.f7) (Frankel and Young 1998; Nielsen, Pedersen et al. 2005). 
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Figure 1.f7. Lentivirus life cycle.  
 
The picture describes the HIV virus life cycle: interaction and integration with the host, 
transcription, viral particles assembly and as last endocytosis mediated release.  The 
picture was made by Dyana Terry Soenz from Poeschla’s lab and it was downloaded 
online at http://mayoresearch.mayo.edu/mayo/research/poeschla/index.cfm 
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Name of protein Function  Transcript 
MA, matrix Viral assembly, facilitates 
infection in non-dividing 
cell types 
Gag 
CA, capsid Structural protein Gag 
NC, 
nucleocapsid  
Structural protein Gag 
p6,  Mediate the release of 
particles 
Gag 
SU, surface 
protein or gp120 
Surface receptor Env 
TM, 
transmembrane 
protein or gp41 
Surface receptor Env 
PR, Protease Protein cleavage Pol 
RT, Reverse 
transcriptase 
reverse transcription Pol 
IN, Integrase Viral genome integration Pol 
Vif Found in the viral particle Vif 
Vpr Found in the viral particle Vpr 
Nef Found in the viral particle Nef 
Tat Gene regulatory function Part of Vpr-
Vpu-Env 
Rev Gene regulatory function Vpu-Env 
Vpu Indirectly assist the virion 
assembly 
Env 
 
Table 1.1.t1. Table of the HIV proteins (Frankel and Young 1998).  
 
1.4.3 LENTIVECTOR SYSTEMS 
 
The production of lentiviral vectors relies on splitting the necessary 
components into several plasmids, called packaging (encoding viral genes 
required for vector production but not incorporated into the vector 
genome), envelope (encoding a heterologous envelope protein for 
pseudotyping, commonly VSV-G) and transfer (encoding the transgene 
cassette and cis-acting sequences required for vector production, reverse 
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transcription and integration) plasmids. In this study second- and third-
generation LV were used. Lentiviral generations refer to the genes 
encoded by the packaging plasmids. A second-generation system includes 
gag, pol, tat and rev, while a third-generation system uses only gag, pol 
and rev, with the latter one being present on a separate plasmid (Vigna and 
Naldini, 2000). The production on LV particles requires the packaging, 
rev, envelope and transfer plasmids to be co-transfected into producer 
cells. The host cells mainly in use for LV production and used in this 
specific project were the human embryonic kidney HEK293T cell line, due 
to their highly efficient transfection. These plasmids were transfected into 
the HEK 293T cells using a Calcium Phosphate transfection. 
 
1.4.4 IDLVs 
 
The integration process is a pivotal step of the Lentivirus’ life cycle, after 
which the provirus becomes part of the host genome. The Integrase protein 
contained in the PIC complex mediates this step. The integration starts 
with the cleavage of both dinucleotides at the 3’ ends, then the host 
genome is cut and the proviral cDNA is transferred into the gap. Finally 
the gaps are repaired and the ligation occurs. 
The catalytic activity of integrase can be disrupted by mutations, the most 
commonly used leading to a change from aspartic acid 64 to valine on the 
polypeptide chain. This change causes a significant reduction in proviral 
integration, and an increase in the formation of episomal DNA vector 
circles, which can be efficiently transcribed and are metabolically stable in 
non-dividing cells (Leavitt, Robles et al. 1996; Yanez-Munoz, Balaggan et 
al. 2006). Such Integration Deficient Lentiviral Vector (IDLVs) can 
transduce target cells and allow transgenic expression. Dividing cells, as 
the NPCs, can be efficiently transduced by IDLV; in this case the episomal 
vector as well as the encoded transgene are expected to be progressively 
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diluted through cell division (Yanez-Munoz, Balaggan et al. 2006; 
Wanisch and Yanez-Munoz 2009). 
 
1.5 RNAi and shRNA 
 
RNA interference or RNAi is a post-transcriptional regulatory system, 
occurring from nematodes to fungi, and is a very important mechanism by 
which organisms can temporarily interrupt mRNA translation and protect 
themselves from viral attack. It was first described in 1990 by Napoli et al. 
and then by Guo and Kemphues in 1995, both of whom did not have a real 
understanding of the biological significance behind the event they were 
looking at. In the experiment accomplished by Guo and Kemphues, the C. 
elegance par-1 gene expression silencing was attempted and achieved by 
injection of an anti-sense or a sense strand RNA. To have a clarification 
about the mechanism behind the RNA mediated “gene silencing”, we had 
to wait for a 1998 publication in Nature by Fire et al. In this paper they 
reported a strong “gene silencing” mediated by double-stranded RNA. At  
most a modest effect was found when a single-stranded RNA (sense or 
anti-sense) was injected. They coined the term RNAi to describe the event, 
and Fire and Mello were awarded with a Nobel Prize in 2006.  
 
The interference system acts through small pieces of RNA (21-23 nt), 
obtained from a double strand RNA (dsRNA), cleavage by the 
endoribonuclease DICER. The short RNA is recruited by the RNA-
induced silencing complex (RISC), which once assembled with the 
siRNA, is able to recruit the complementary or partially complementary 
mRNA, and produces respectively degradation or silencing (Figure 1.f8) 
(Kim and Rossi 2007). 
 
Using the RNAi pathway, the shRNA can silence or degrade mRNA and 
can be a powerful tool for gene therapy. The shRNA is a small sequence of 
RNA that can shape as hairpin and is widely in use for gene silencing by 
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blocking mRNA translation. It can be delivered by viral (for example LVs) 
and non-viral vectors,  (McIntyre and Fanning 2006; Mahmood ur, Ali et 
al. 2008). 
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Figure 1.f8. iRNA by Kim and Rossi 2007 (Strategies for silencing human 
disease using RNA interference).  
 
RNAi is a mechanism by which organisms can block mRNA translation and self-protect 
against some recognized viruses. The mechanism is mediated by a double strand RNA 
and is in turn recognized and cleaved by the ribonuclease DICER, once the siRNA is 
produced, and can interact with the RISC complex. Once the RISC is bound, it recognizes 
and activates mRNA cleavage.  
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!!!!!!!AIMS OF THE PROJECT 
 
As the growing body of evidence suggests, neurogenesis occurs in 
pathological conditions such as stroke, neurodegenerative diseases and 
severe brain damage. The exact role of this event is not completely 
understood and has not yet been clarified. In order to better understand 
SVZ neurogenesis in ischemic conditions, this project aims to boost and 
inhibit neurogenesis and assess the effect of the treatments in a long-term 
study.  
 
The project can be divided in four separate aims: 
1. To set up a neurogenesis inhibition system based on LVs 
2. To set up and validate an MCAo model for long-term study 
3. To set up an LV-based system to detect and quantify neurogenesis 
in vivo in the presence or absence of stroke 
4. To study the effect of SVZ neurogenesis modulation on post-
ischemic recovery. 
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CHAPTER 2 
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MATERIALS AND METHODS 
 
 2.1 CLONING  
2.1.1 STANDARD CLONING TECHNIQUE  
 
The plasmids used for this project were designed using Vector NTI 
software from Invitrogen, and the production was achieved through 
techniques of molecular biology.  
 
The plasmid DNA was first amplified by heat shock transformation in Top 
10 E. coli cells. Bacteria that incorporated the exogenous DNA or 
transformed bacteria, acquired one or more antibiotic resistance that was 
encoded in the plasmid; these resistance was then used to select the desired 
colony. In this case an ampicillin resistance was encoded in the plasmid 
DNA sequence. Once the plasmid was incorporated in the bacteria the 
cells acquired the resistance and there were selected by growing in an 
Ampicillin enriched medium (both techniques are described below). 
 
After the colony was amplified, the DNA was extracted and enzymatic 
digestions were used to excise the undesired sequences from the original 
plasmids; compatible ends were bounded by Ligase T4 reaction. 
 
To ensure the correct sequence on the selected plasmid, enzymatic 
digestions were used as well as the plasmid was entirely sequenced as 
below reported. 
 
2.1.1.1 RESTRICTION ENZYME DIGESTS 
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The DNA extracted from Top ten E. Coli cells was cut by digestion with 
restriction enzymes, selected in order to obtain compatible strand ends to 
be successively ligated by the T4 Ligase reaction. 
 
20 µl of total digestion reagents, contained 2 µl of enzyme’s buffer, 1 µl of 
the selected restriction enzyme and 1 µg of plasmid DNA, was mixed and 
incubated over night at 37°C. The reaction efficiency was estimated by gel 
electrophoresis, from which the correct size band was assessed and 
purified.  
 
2.1.1.2 GEL ELECTROPHORESIS AND DNA EXTRACTION 
 
MATERIALS 
 
Loading buffer, Sigma 
Agarose, Sigma 
Ethidium bromide, Sigma 
GeneRuler 1 kb, Fermentas 
QIAgen gel extraction kit, QIAgen 
 
SOLUTIONS AND BUFFERS 
 
 10X TAE  
48.4 g of Tris base [tris(hydroxymethyl)aminomethane] 
         11.4 ml of glacial acetic acid (17.4 M) 
3.7 g of EDTA, disodium salt 
Deionized water 
 
The 1X TAE was obtained in a 1:10 dilution. 
 
 
Digested DNA was re-suspended in loading buffer, and loaded in 0.8% 
agarose gel containing 0.5 µg/ml of ethidium bromide; as a DNA reference 
the GeneRuler ladder 1 kb was used. DNA was run in 1% TAE buffer at 
50 V for 30-45 minutes. 
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After electrophoresis, DNA fragments were detected by illumination under 
UV light, and the correct size band was excised from the gel and purified 
with the QIAgen extraction kit, following manufacturer’s instructions. 
Briefly, the cut band was first weighted; 3 volumes of buffer QG (w/v) 
were added per unit of gel slice and incubated at 50°C for 10 minutes. 1 
gel unit of isopropanol was added to the solution and applied to a 
QIAquick spin column, then centrifuged for 1 minute. The flow-through 
was discarded and 0.5 ml of buffer QG was added to the column and 
centrifuged for one more minute. 0.75 ml of PE buffer was added to the 
column and washed out by centrifugation. The column was placed in a 
clean tube and the DNA eluted with 30 µl of EB.   
 
2.1.1.3 KLENOW POLYMERASE REACTION  
 
Klenow Polymerase, Promega 
Klenow Polymerase Buffer, Promega 
BSA, Promega 
 
Klenow Polymerase allows filling 5’ ends obtained by specific enzymatic 
digestion. 
The reaction mixture contained 2.5 µl of DNA (0.1-1 µg), 1 µl of Klenow 
Polymerase buffer, 2 µl of dNTPs 2 mM, 1 µl of BSA and 2.5 µl of water; 
the solution was incubated for 1 hour at room temperature, and 
successively the enzyme activity was stopped in a 75°C thermostat for 10 
minutes.   
 
2.1.1.4 LIGATION 
 
MATERIALS  
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T4 Ligase, Promega 
T4 ligase Buffer, Promega 
BSA 10%, Promega 
 
DNA fragments were ligated together with a T4 Ligase reaction; a starting 
amount of 100 ng of Backbone DNA was used. The insert concentration 
was calculated with the following formula: 
(1) !"!!"#!"# ÷ !"!!"#$%& = !"!!"#$!%&' ÷ !"!!"#$!%&' 
(2) !"!!"#$%& = !"#$%&#'!(× !"!!"#$%&!"!!"#$!%&' 
 
Depending on the structure of the ends of the molecules (two sticky ends, 
two blunt ends or one sticky and one blunt end) the equation in (1) 
becomes: 
 
To join two sticky ends 
 
(3) !"!!"#$%& ÷ !"!!"#$%& ×3 = (!"!!"#$!%&' ÷ !"!!"#$!%&')×1 
To join one sticky end and one blunt 
          
(4)! !"!!"#$%& ÷ !"!!"#$%& ×5 = (!"!!"#$!%&' ÷ !"!!"#$!%&')×1 
 
To join two blunt ends 
         
(5)! !"!!"#$%& ÷ !"!!"#$%& ×10 = (!"!!"#$!%&' ÷ !"!!"#$!%&')×1 
 
10 µl of the ligation mix contained 1% of BSA 1 µl, 10% of ligase buffer 1 
µl, DNA as calculated above, 1 µl of T4 Ligase, and water. The reaction 
was incubated over night at 18ºC. The day after, the ligated DNA was 
introduced into the bacteria by heat shock transformation, clones selected 
with ampicillin, amplified and DNA extracted (see below).  
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2.1.1.5 BACTERIAL TRANSFORMATION and CLONE                      
AMPLIFICATION 
 
MATERIALS  
 
LB Broth, Sigma  
Bacteriological Agar for Molecular Biology, Sigma 
Ampicillin, Sigma    
                  
1-1.5 µl of plasmid DNA was introduced in Top ten competent cells by 
heat shock transformation.  E. Coli Top ten cells stored at -80°C were 
slowly defrosted on ice and the DNA added to the tube. DNA 
incorporation was heat induced; the bacteria-DNA solution was placed at 
42ºC for 45 seconds, then quickly the tube was put back on ice. 
Transformed bacteria were incubated for 1 hour in an antibiotic free LB 
medium at 37°C, then spread onto ampicillin plates and incubated over 
night at 37°C.  The day after, the positive clones were selected and 
amplified in the conditional LB medium.  
 
2.1.1.6 PLASMID DNA EXTRACTION  
 
MATERIALS 
 
Miniprep and Maxiprep kit, QIAgen  
 
Plasmid DNA extraction from bacteria was achieved by QIAgen Miniprep 
and Maxiprep. For 1 to 5 ml (150 to 500 ml for Maxiprep) of inoculated 
bacteria 250 µl of P1 buffer was added (10 ml for Maxiprep), followed by 
250 µl of P2 buffer and 350 µl of P3 buffer (10 ml of each buffer for 
Maxiprep), each time gently inverting the tube 4-6 times (Maxiprep were 
incubated on ice for 30 minutes). The tube was centrifuged at 13,000 rpm 
for 10 minutes (Maxiprep were centrifuged at 3500 rpm for 30 minutes), 
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and the supernatant added to the QIAprep spin column. The tube was 
centrifuged at maximum speed and the flow-through discharged 
(Maxiprep were filtered by gravity and the flow-through collected in a 50 
ml falcon tube). After washing with 500 µl of PB buffer and 750 µl of PE 
buffer the DNA was eluted with 50 µl of EB buffer. In the case of 
Maxiprep, 10 ml of QBT buffer was used to equilibrate the Quiagen-tip 
500, and then the flow-through was applied to the column, as well as 2 x 
30 ml of buffer QC. The DNA was eluted by adding 15 ml of buffer QF; it 
was then precipitated with 10.5 ml of isopropanol and centrifuged at max 
speed for 30 minutes. After discharging the liquid and let the DNA air dry, 
the pellet was re-suspended in a suitable volume of TE buffer.  
 
2.2 LENTIVIRAL VECTOR PRODUCTION 
 
2.2.1 CELL LINES 
 
MATERIALS  
 
DMEM, PAA 
FBS, PAA  
Penicillin and Streptomycin , PAA 
Trypsin/EDTA solution , PAA 
PBS, PAA 
 
All cell lines used were maintained in a Dulbecco’s modified medium 
enriched with 10% foetal bovine serum and antibiotics 
(streptomycin/penicillin), under 5% CO2 and controlled humidity. The 
cellular confluence was tightly controlled, and was not allowed to expand 
for more than 80% of the total free surface.  
Cells used in the project: 
 
 
53 
 
• HEK 293T is the human kidney epithelial cell line engineered to 
constitutively express the SV40 large T antigen. The HEK 293T cell line 
was used to produce LV. 
• HeLa cells are human fibroblasts isolated from a patient who had cervix 
cancer in 1951. These cells respond very well to LV transduction and were 
used for titration. 
• NIH3t3 cells are mouse fibroblasts. These cells have an overexpression 
of the v-H-Ras protein, in turn responsible for an increase level of Cyclin 
D1 (Liu, Chao et al. 1995). The increased amount of Cyclin D1 produces a 
shorter G1 and it is responsible for the tumorigenic phenotype. This cell 
line was used to assess variation of CyclinD1 protein content and the cell 
cycle blocking, as effect of the LVs_dnCyclinD1 and 
LVs_shRNA_CyclinD1 transduction.  
 
2.2.2 VECTOR PREPARATION 
 
MATERIALS  
 
Water, Sigma-Aldrich 
2.5 M CaCl2, Sigma-Aldrich 
HEPES, Sigma-Aldrich 
NaCl, Sigma-Aldrich 
Na2 HPO4, Sigma-Aldrich  
Polybrene, Sigma-Aldrich 
DNAse I, Promega 
TE endotoxin free, Quiagen 
Filter 0,22-µm-pore-size, Nalgene 
 
Third or second generation HIV-based LVs  was obtained via transfection 
of respectively four and three plasmids into HEK 293T cells (Yanez-
Munoz, Balaggan et al. 2006). 
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CALCIUM PHOSPHATE TRANSFECTION 
2-2.5 x106 cells were plated two days before transfection in a 15 cm plate; 
this cellular concentration produces two days later a transfection optimum 
confluence (60-70%). 
 
LVs were produced by Calcium Phosphate transfection. On the 
transfection day, between 1 and 4 hours before starting the procedure, the 
medium was replaced with 18 ml of fresh DMEM,. 
To optimize vector packaging the following molar DNA ratios were used:  
  
1. For a third generation LV 
                 Env (pMD2.VSV-G): rev (pRSV-REV): packaging (pCMVΔR8.74): transfer plasmid = 1:1:1:2 
 
2. For a second generation LV  
                 Env (pMD2.VSV-G): Packaging (pMDLg/pRRE): transfer plasmid = 1:1:2  
 
The plasmid DNA mixture was re-suspended in TE buffer and water; the 
final concentration for the TE solution was 0.1 %. 
 
DNA complexes were induced by adding 125 µl of CaCl2 drop-by-drop 
while vortexing for 1 minute, then 1’250 µl of 2xHBS were added.  
 
The solution contained the DNA complexes were added to the cells and 
left 14-16 hours in the incubators. At 16 hours, the medium was replaced 
with a fresh one. 
 
The vectors were harvested at 48 and 72 hours post-transfection. 
 
HARVESTING 
The medium was collected and centrifuged at 2,500 rpm for 10 minutes, 
and then the supernatant filtered via a 0.22 µm pore size. Vector 
concentration was achieved by overnight centrifugation at 4,000 rpm and 
4°C. The day after, the supernatant was discarded and the pellet re-
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suspended in 50 µl of DMEM with no supplements.  To remove debris, 
LVs were centrifuged for 10 minutes at 4,000 rpm and 4°C; finally DNAse 
5 u/ml and MgCl2 10 mM was added to the collected supernatant. 
 
2.2.3 TITRATION 
 
MATERIALS 
  
Polybrene, Sigma-Aldrich  
PFA, Sigma-Aldrich  
 
HeLa cells were used to titrate LVs. We used two titration systems; one 
was based on eGFP expression estimated by Flow Cytometry, while for all 
vectors without an eGFP cassette, the titre was estimated by qPCR.  
 
2.2.3.1 FLOW CYTOMETRY 
 
TRANSDUCTION 
At day zero 105 cells were plated out per six well plate well. The day after, 
the cells were transduced by replacing the medium with 2 ml of fresh 
DMEM containing Lentivector particles. To titrate each batch, ten-fold 
vector dilutions were prepared in complete DMEM; the range used for the 
transductions was from 10-3 to 10-6. 8 µg/ml of polybrene was added to the 
plates to improve transduction efficiency. 3 days later cells were harvested 
and fixed in 1% PFA. 
 
ESTIMATION OF INFECTION UNITS 
The number of eGFP positive cells per sample was estimated by Flow 
Cytometry. Transduction occurs by multiple or single infection events per 
cell; in order to estimate the number of vectors based on the number of 
green cells, it is important to exclude samples for which the possibility of 
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multiple infection events is high. Based on the assumption that with less 
than 10% of green cells, the transduction event occurs only by a single 
infection, the number of green cells could be used as a good estimation for 
the number of vectors originally present during the transduction. The titre 
was expressed in Transducing Units per millilitre (TU/ml) and was 
calculated using the following formula: 
 
(6) !"#$!!"#$%&'("! "#$/!"(!"/!") != [!×!! ]×! 
 
F = frequency of green cells 
C = total number of cells at day zero 
V = volume of inoculum  
D = Lentiviral vector dilution 
2.2.3.2 qPCR 
 
MATERIALS 
DNeasy blood & tissue kit, QIAgen 
TaqMan, Applied Biosystems 
SensiMix Syber No Rox Kit, Bioline 
Ethanol 99-100%, Sigma-Aldrich  
 
Vectors without a functional eGFP cassette were titrated by qPCR.   
 
TRANSDUCTION 
The day before transduction 105 cells were placed in a six well plate; 24 
hours later the transduction was performed. For each batch two serial 
dilutions were prepared: 1:2,000 and 1:20,000 that for a 108IU/ml vector 
correspond to MOIs 0.5 and 0.05.  One day after the cells were harvested; 
the DNA was extracted using the DNeasy blood and tissue kit from 
QIAgen, and eluted in 400 µl of PBS.  
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DNA EXTRACTION 
For the DNA extraction 20 µl of Proteinase K and 200 µl of AL buffer 
were added together, placed in a 56°C bath and incubated for 10 minutes. 
After adding 200 µl of Ethanol 99-100% the samples were loaded onto a 
DNeasy Mini spin column and centrifuged at 800 rpm for 1 minute. After 
discharging the collecting tube and the flow-through within, the buffers 
AW1 and AW2 were added to the column. Each buffer was centrifuged at 
800 rpm for 1 minute and consequently flow-through discharged. The 
DNA was eluted from the column with 200 µl of AE buffer.  
 
qPCR REACTION  
Two different reactions were conducted separately for the titration of the 
lentivectors: the LRT reaction quantified the number of copies of the 
lenti_backbone, while the Actin reaction quantified the number of Actin 
gene copies in the sample.  
 
LRT reaction, LVs copies number:  
Sample volume = 6.25 µl 
Primer concentration= 300mM 
Standards=102-107 copies of pHR’SIN-cPPT-SEW/reaction 
Starting cycle: 50°C 2 minutes, 95°C 10 minutes, 50x (95°C 15 sec, 60°C 
1 minute) 
 
Actin reaction, internal standard: 
Sample volume= 5 µl 
Primer concentration= 300mM 
Probe concentration=200 mM 
Standards=10-106 copies Hela cell equivalents (genomic DNA) 
Starting cycle: 50°C 2 minutes, 95°C 10 minutes, 50x (95°C 15 sec, 60°C 
1 minute). 
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The number of LRT copies normalized to cell number using the Actin 
gene is a very sensitive estimation of the vector genome copies that have 
completed reverse transcription per transduced cell, and it can be used for 
the estimation of vector titre.  
Formula to estimate the vector titre: 
 
(7) !"/!" = (#!"!!"#$%&!!"#!!"#×!")(#!"!!"#$%&!!"#!!"#$%×!")×!×!  
 
 
D = dilution factor 
C = total number of cells at day zero (#!"!!"#$%&!!"#!!"#×64)= total number of LRT copies in the 
transduced sample !(#!"!!"#$%&!!"#!!"#$%×80)= total number of actin copies in the 
transduced sample 
 
 2.3 IN VITRO TRANSDUCTION FOR CyclinD1 
DOWN-REGULATION  
 
 MATERIAL 
 
Polybrene, Sigma-Aldrich 
 
After packaging, LVs_dn_Cyclin D1 and LVs_shRNA were tested for 
their in vitro effect on the NIH3t3 cell line by using a viability assay and 
Western blot.  
 
 
2.3.1 TRANSDUCTION  
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At day zero, 2.5 x 105 cells were plated in a serum enriched medium; the 
transduction was performed the day after with 8µg/ml of Polybrene. 
 
The multiplicity of infection (MOI) is a parameter used to standardize the 
amount of virus or vector added per cell for in vitro treatments; in the case 
of vectors: 
 
MOI = Transducing Units / cell 
 
 2.4 VIABILITY ASSAY  
 
2.4.1 MTT 
 
MATERIAL 
 
Thyazolyl Blue Tetrazolium Blue (MTT), Sigma-Aldrich 
DMSO, Sigma Aldrich 
 
The viability assay was used to diagnose the effect of dnCyclin D1 and 
shRNA_Cyclin D1 on the NIH3t3 cell cycle. 
 
At day zero 0.5 x 105 cells were placed in a 6 well plate and were 
transduced the day after. The viability assay was performed by adding 100 
µl of MTT for 4’000 cells and incubating for 3 hours at 37°C. After 
incubation the medium containing MTT (5 µg/ml) was discharged and the 
plates were left to dry overnight at room temperature. 250 µl of DMSO 
was used per well to dissolve the crystals formed from the reaction 
between MTT and the mitochondrial enzyme Reductase. The samples 
were analysed by spectrophotometer at λ = 570 nm. Because the Reductase 
is directly proportional to the number of cells metabolically active, the 
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absorbance produced by the reaction with MTT is directly proportional to 
the live cells number and can be used to estimate their concentration. 
 
 2.5 PROTEIN ANALYSIS  
 
!!!!!!2.5.1!WESTERN!BLOT!
 
MATERIALS  
 
Complete EDTA free lysis buffer, Roche 
Protein quantification, Bio-Rad 
Immobilon P transfer membrane, Millipore 
Sodium dodecyl sulphate, Sigma-Aldrich 
2-mercaptoethanol, Sigma-Aldrich 
TRIZMA, Sigma-Aldrich 
Glycine, Sigma-Aldrich 
NaCl, Sigma-Aldrich 
Tween 20, Sigma-Aldrich 
Glycerol, Sigma-Aldrich 
Dried milk, Tesco  
 
SOLUTIONS AND BUFFERS 
 
1. Laemmli Buffer 2X 
4% SDS 
10% 2-mercaptoethanol  
20% Glycerol 
0.125 M TRIZMA 
pH 6.8 
 
2. Migration Buffer 10X 
0.25 M TRIZMA 
1.9 M  Glycine 
1% SDS 
pH 8.3 
 
3. Transfer Buffer 10X  
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            48 mM TRIZMA 
39 mM Glycine 
0.375% SDS (37.5 ml of 10% SDS) 
 
Cells were transduced with the method previously described, harvested by 
adding 50 µl of complete EDTA-free lysis buffer and scraped from the 
plate using a cell scraper. The lysate was spun at high speed, and the 
supernatant collected and stored at -80°C.  
 
PROTEIN CONTENT ASSAY 
Protein concentration, expressed in µg/µl, was estimated by Bio-Rad 
protein assay. Briefly, after obtaining a dilution of 1-5 times for each 
protein sample, 160 µl of the standard or the sample was added to the well 
in a 96 well plate; 40 µl of the dye reagent was added soon after. Because 
the protein interaction with the dye causes a colour change in a 
concentration dependent manner, using the BSA standard samples is 
possible to build a standard curve that matches absorbance with protein 
concentration. The standard curve allows the estimation of the protein 
content in the unknown samples (protocol available through Thermo 
Scientific web site, TECH TIP #57). 
 
SDS-PAGE GEL   
The samples were denatured by incubation with Laemmli buffer at 95°C 
for 10 minutes. Denatured proteins were loaded in a 12% SDS-Page gel by 
which they were separated according to size. Gels were placed in a Bio-
Rad apparatus and covered by 1x migration buffer. Introducing a potential 
difference of 200 V for 1-1.5 hours in the apparatus, subsequently induced 
migration.  
The electro-transfer technique allowed protein mobilization from a gel to 
an Immobilon P membrane. For the electro-transfer, a sandwich like 
structure was built using sponges with some Whitman paper and in the 
middle the membrane facing the gel. 
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The blotting was loaded in a transfer buffer with the same Bio-Rad 
apparatus used for protein separation. For the electro-transfer 100 V was 
applied for 1 hour.  
 
2.5.2 IMMUNO REACTION 
 
MATERIALS  
 
Tween 20, Sigma-Aldrich 
Milk, Tesco 
PBS tablets, Sigma-Aldrich 
Mouse anti Cyclin D1, # C7464, Sigma Aldrich 
Rabbit anti alpha tubulin, # T8660, Sigma Aldrich 
Goat anti mouse 800, # 926-31066, Odyssey® 
Rabbit anti goat Alexa fluor 680, #A20984, Invitrogen 
 
SOLUTIONS AND BUFFERS 
 
PBS_T 
Phosphate buffer saline 1 M 
Tween 20 0.025% 
 
BLOCKING SOLUTION 
PBS_T 
Milk 5% 
 
After the electro-transfer the membrane was incubated for 1 hour at room 
temperature in blocking solution, then overnight at 4°C with the antibody 
of interest diluted in the PBS-T buffer. The day after the membrane was 
washed twice in PBS-T, and incubated for 1.5 hours at room temperature 
with the secondary antibody. The antibodies’ concentration used is 
described in Table 2.1.t1 
After incubation the membrane was washed twice in PBS_T and analysed 
by Odyssey technology. 
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Antibody company concentration 
Anti-mouse Cyclin D1 Invitrogen 1:1000 
Anti-rabbit alpha tubulin Invitrogen 1:1000 
Alexa Fluor, Goat anti 
rabbit 680 
Invitrogen 1:30,000 
Alexa Fluor  Donkey anti 
mouse 700 
Invitrogen 1:30,000 
 
Table 2.1.t1. Antibodies concentrations used in the western blot assay. 
 
2.6 IN VIVO STUDY  
 
2.6.1 ANIMALS 
 
All procedures in live animals conformed with Animals (Scientific 
Experimentation) Act 1986, were carried out under the appropriate UK 
Home Office licences, and had LREC approval. 
 
Six-ten week old male C57BL/6 mice were used to perform MCAo; this 
strain has a reduced Willis Circle’s posterior communicating artery, in turn 
responsible for a high sensitivity to ischemia. These are widely used to 
produce the Middle Cerebral Artery occlusion model or MCAo (Fujii, 
Hara et al. 1997; Small and Buchan 2000).  
 
All experiments were conducted blind; the animals were randomized and 
injected with a coded viral batch. A colleague, who was neither familiar 
nor involved in this study, prepared the coded vials and prepared a sealed 
envelope with the key to the batches used. The envelope was opened only 
after terminating the histological cell quantification.  
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Females were excluded from the project as the oestrus cycle hormones 
(estradiol and estrogens) produce arterial vasodilatation and improve 
endothelial functions; this is reflected in a reduction of cardiovascular 
disease risk factor, and provides an active protection from ischemia 
(Etgen, Jover-Mengual et al.). In addition, female hormones have a 
protective effect that might interfere with the results and data analysis.  
 
2.6.2 ANIMAL MODELS  
 
An animal model is a powerful tool to investigate diseases; the main idea 
is to reproduce a specific human condition in order to examine it and 
develop possible therapies.  
There are a number of ways to validate an animal model:  
• Predictive validity, the ability to respond to drugs, already in use to treat 
the disease the model is meant to reproduce. 
• Construct validity, refers to the theoretical clarification of how and why 
an animal model would mimic a human disease.   
• Etiological validity, the etiology of the model and the disease of the 
model is meant to emulate must have points in common.    
• Face validity, refers to the phenomenological similarity between the 
behaviour shown by the model and symptoms related to the disease. 
 
It is very unlikely that a model has all of these qualities simultaneously, 
but a good model could only have one or two of them. 
The MCAo produces severe neuronal damage and death within the 
striatum cortex and the hippocampal formation, and is therefore widely 
used as focal ischemia model.  
2.6.3 MCAo MODEL  
 
MATERIALS: 
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Isofluorane, Baxter 
 
The MCAo is performed under general anaesthesia using a mix of 
isoflurane, oxygen and nitrous oxide. The anaesthesia effectiveness was 
assessed by paw pinching and constantly monitored during the surgery.  
 
The procedure was performed through a midline incision of the neck and 
the subsequent isolation of the right common carotid artery at the level of 
its bifurcation, from which the internal and the external carotid originate 
(Figure 2.f1). The blood flow was interrupted through the use of four 
knots, two located in the common carotid at different levels and one in 
each branch of the upper bifurcation. The protocol used in this project to 
induce permanent and temporary MCA occlusion is currently in use, and it 
was previously described by Gibson and Murphy 2004 (Gibson and 
Murphy 2004). 
 
Once the blood flow was interrupted, and a small hole was produced on 
the artery’s wall, a 6-0 monofilament nylon suture, coated with clear 
silicon was inserted and advanced up the ICA to the level of the Middle 
Cerebral Artery. This model produces major neurodegeneration and 
cellular damage in the ipsilateral hemisphere, although minor effects are 
visible also in the contralateral.  
 
Different variations of the model based on the occlusion time were 
investigated in this project. For the permanent_MCAo, pMCAo, the 
filament was permanently left in place, while for the temporary_MCAo, 
tMCAo, it was alternately left for either one hour (1h_MCAo) or thirty 
minutes (30’_MCAo). The temporary occlusion of the MCA is associated 
with reperfusion that occurs with the blood flux restoration. The 
reperfusion is responsible for oxidative stress and a mechanical increase of 
the blood pressure; both factors are responsible to increase cellular damage 
and neuronal degeneration.  
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Some negative control animals were included, that underwent “sham” 
surgery. The sham animals were produced in two different ways; for the 
pMCAo, the sham received only the carotid dissection and its exposure. In 
the tMCAo model, after the cerebral occlusion, the normal flow was not 
completely restored, because a small piece of filament was left in the main 
carotid. For this reason, in the sham animals produced in the experiments 
involving the tMCAo, the main carotid was exposed and a small piece of 
the filament was left in the main branch. 
 
After the surgery the animals were placed on a heat pad and wet pellet was 
administrated in a petri-dish at least for one week after the ischemic event.  
 
 
 
 
 
 
 
 
 
67 
 
  
 
Figure 2.f1  Oxygenated blood circulatory system of a rodent. 
The common carotid brings the oxygenated blood from the Aortic arch to the head. The 
bifurcation divides the common carotid in an external and an internal branch. The Middle 
Cerebral Artery is the extension of the internal carotid; this artery delivers oxygenated 
blood to the Circles of Willis. This key structure is responsible for the reduction in aortic 
blood pressure and flow sorting in the main vessels. The occlusion of the Middle Cerebral 
Artery interrupts the blood flux and is responsible for neuronal damage and death. The 
picture was on line downloaded at 
http://www.biologycorner.com/worksheets/rat_circulatory.html.  
 
 
 
        2.6.4 INTRACRANIAL INJECTIONS 
 
MATERIALS: 
 
Hypnorm, Vetapharma  
Hypnovel, Roch 
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Animals were anesthetised using an intraperitoneal injection of a mixture 
of Hypnorm, Hypnovel and water (1:1:2). After a complete anaesthesia 
was induced, they were placed in a stereotactic frame having the head 
blocked by ear bars and a mouth bar. The skin was cut and the skull 
exposed and drilled, then the syringe electronically inserted through it. A 
micro pump was used to slowly introduce the fluids in the brain. For the 
SVZ modulation in absence of stroke, two bilateral injections, 5µl of LV, 
were performed at the beginning of the RMS. For the SVZ modulation in 
ischemic conditions 4 injections, 3 µl each of LV, per brain, were 
performed. The animals were returned to their cage and 3 weeks after they 
were killed by transcardial perfusion. The brains were processed as 
described below:  
 
The bregma was used as a reference, and alternatively the beginning of the 
RMS or the SVZ was injected. For the RMS the coordinates used were 
previously described by Goncalves B. et al. (2008), AP 0.75, ML 1.2, DV 
-1.7 (Goncalves, Suetterlin et al. 2008). SVZ injections were designated 
according to our preliminary experiments (Figure 2.f2). From preliminary 
data, the majority of the damage was located around bregma AP ±1. Since 
the SVZ neurogenic islands are mostly concentrated in the front brain, as 
the literature suggested, and the strength of the SVZ response is closely 
dependent on the distance to the neurogenic islands and the damage 
severity, we decided to select the SVZ injection sites as the closer regions 
to the front ischemic damage produced by 1h_MCAo Figure 2.f2. The 
coordinates were the following: SVZ_1 (AP, 0.25; ML, ± 0.96, DV -2.75), 
and SVZ_2 (AP, 0.86; ML, ± 0.72, DV -3). 
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Figure 2.f2. Ischemic areas induced by for 1h_MCAo.  
 
The picture shows the localization of the ischemic areas for 1h MCAo subjects.  Each dot 
represents a single brain slice located at a specifically identified distance from bregma. In 
green the damage produce in the hippocampal formation between AP -0.94 and -4.24; in 
red the damage involved the front brain, AP 1.94 and -2.30 (sensorimotor cortex and 
striatum). The majority of the damage was located between bregma AP -1 and +1. n=7.    
 
 
2.6.5 BEHAVIOURAL TESTS 
 
MCAo animals were tested for their sensorimotor behaviour by the 0-28 
focal deficit test (Clark, Gunion-Rinker et al. 1998). This test is based on 
observations of the sensory-motor behaviour developed post-surgery, and 
it is meant to detect damage in the somato-sensory (S1), motor cortex (M1, 
M2), and striatum. The use of a grid allows detecting defect in 
coordination, weakness, and motor deficit. This test comprises multiple 
tasks, for each of them a score from 0 to 4 was assigned (0=normal, 
4=maximum defect). The final result is the sum of all the scores given for 
each task.  
The tasks are described below: 
1. Body Symmetry. To detect M1 and 2 damage. The animal is 
lifted through its tail and the asymmetry is observed between 
           DORSAL AND VENTRAL 
             HYPPOCAMPUS  
                 AP -0.94/-4.24 
                        STRIATUM-M1 and S1 
                            AP +1.94/-2.30 
ANTERPOSTERIO
ISCHEMIC AREA INDUCED BY 1h_MCAo 
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forelimbs and hind-limbs.  A score zero is assigned for a normal 
phenotype, one for a slight asymmetry, two for a moderate 
asymmetry, three for a prominent asymmetry and four for an extreme 
asymmetry. 
2. Gait. To detect M1, M2 and striatal damage. The animal is left 
free to move and its gait is observed.  A score zero is assigned for a 
normal gait, one if  its gait looks stiff and/or inflexible, two if it limps, 
three if it shows trembling, drifting and/or falling and four if it doesn’t 
walk at all. 
3. Climbing.  To detect M1, M2 and striatal damage. The animal is 
located on a centre of a grid, and after the grid is inclined 45° the 
motor behaviour is observed.  A score of zero is assigned for normal 
climbing, one if it climbs with strain and limb weakness, two if it 
holds onto slope or it does not climb, three if the animal slides down 
slope and shows unsuccessful effort to prevent fall or four if it slides 
immediately and does not try to prevent fall. 
4. Circling behaviour. To detect M1 and M2. Movement is observed 
when the animal is on its cage and left free to move on the bench. A 
score of zero is assigned when no circling behaviour is observed, one 
when the animal turns predominantly to one side, two when it is 
irregularly circling to one side, three when this circling is constant and 
four when it is pivoting, swaying or does not move at all. 
5. Front limb asymmetry. To detect M1 and M2 damage. The front 
limbs are observed by lifting the animal’s tail as well as allowing it to 
move freely on the bench. A score of zero is assigned for a normal 
symmetry, one when the asymmetry is slight, two when a marked 
asymmetry is present, three for a prominent asymmetry and four when 
it does not move any limb and/or the body. 
6. Compulsory circling. To detect striatal damage, the animal is 
observed on its cage and ambulating on the bench. A score of zero is 
assigned when no compulsory circling is present, one when a 
tendency to turn to one side is observed, two when the animal makes 
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circles to one side, three if it pivots to one side sluggishly and four if it 
does not advance. 
7. Whisker response. To detect S2 damage. The whiskers are lightly 
touched and the response on its face and limbs is observed. If the animal 
shows symmetrical response a score zero is assigned, one for a light 
asymmetry, two for a prominent asymmetry, three when the ipsi-lateral 
response is absent and contralateral response is diminished, and four when 
bilateral proprioceptive response is absent .  
 
2.6.6 ASSESSMENT OF RECOVERY BY WEIGHT 
RESCUE 
 
Surgery causes fluids to be lost as well as a release of stress hormones. 
Both factors affect animal body weight. Post-surgery weight recovery is a 
general indicator for the animal heath, and it is a well-accepted system to 
monitor post-surgery recovery (Modo, Stroemer et al. 2000; Ashioti, 
Beech et al. 2007).  
 
2.6.7 TRANSCARDIAL PERFUSION 
 
MATERIALS: 
 
Paraformaldehyde, Sigma-Aldrich 
PBS tablets, Sigma-Aldrich 
Dolethal, Vetoquinol 
 
       Animals were killed by transcardial perfusion at different times after 
surgery. An appropriate dose of intraperitoneal injection of pentobarbital 
was used to induce deep anesthesia, whence the ribs were cut out and the 
heart exposed. Blood was drained from a laceration in the right atrium, and 
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a needle connected to the peristaltic pump was inserted on the left 
ventricle. The perfusion was performed by delivering an appropriate 
volume of PBS solution to avoid intravascular thrombi; to fix tissues, a 
second cycle of 4% PFA at 4 °C was transcardially administrated. Tissue 
fixation was evaluated by hand skin colour (turned white) and the muscle 
rigidity. The brain was dissected and stored in 4% PFA for no less than 4 
days. .  
 
 2.7 HISTOLOGY  
 
2.7.1 SECTIONING  
 
Different systems were optimised for brain sectioning: cryo-sections for 
cryostat (12-20 µm), paraffin wax-embedded brains for microtome 
sections (6-12 µm) and unembedded, PFA-perfused brains for vibratome 
(50-100 µm). 
 
CRYOSTAT  
To process the brain with the cryostat, the tissues were quickly frozen in 
isopentane at -45°C and stored at -80°C. Half an hour before cutting, the 
brains were acclimatized in the cryostat at -20°C; the cryostat produced 
slices of thickness 16 µm. The sections were left to dry at room 
temperature and then stored at -80°C. Before any histological treatment 
was started brain slices were fixed in 4% PFA and then dried at room 
temperature. 
 
MICROTOME 
To process tissues with the microtome, perfused brains were embedded in 
paraffin by the St George’s Histology facility. 12 µm sections were 
obtained with the microtome and left overnight at 37°C. Before any 
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treatment was performed sections were deparaffinized by Histochoice or 
Xylene.  
 
 
VIBRATOME 
To process tissues with the vibratome, perfused brains were fixed to the 
vibratome plate by super glue, and 50 µm sections were cut.  
 
2.7.2 HISTOLOGICAL ANALYSIS  
          
2.7.2.1 INFARCT VOLUME QUANTIFICATION 
 
The infarct size for animals subjected to pMCAo and tMCAo and killed 
two weeks post-surgery, was estimated by Haematoxylin and Eosin 
staining. This technique is widely used for the assessment of the ischemic 
damage (Isayama, Pitts et al. 1991; Lin, He et al. 1993; Okuno, Nakase et 
al. 2001); differently from 2,3,5-triphenyltetrazolium chloride (TTC) 
staining that it is only applicable when the animal is killed within a week 
post MCAo, it allows damage detection also at later stages (Frankle 1976). 
Unfortunately the sensitivity of the system depends on the damage severity 
and the time between the ischemic event and the animal death. For long 
term experiments, such as one month or more post stroke, an 
Immunofluorescence to detect glia, microglia and neurons can be much 
more informative and sensitive (Chiamulera, Terron et al. 1993; 
Yoshikawa, Akiyoshi et al. 2008; Popp, Jaenisch et al. 2009). For these 
reasons the ischemic volume in long-term MCAo was estimated by 
Immunofluorescence. In this study inflammation, glial scar and 
neurodegeneration were first analysed singularly, and then the average 
between them was uses as best estimation of the ischemic environment 
(Figure 2.f2).  
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For each animal, five regions localized at +2.5, 1.7, 0, -1.7, and -3 mm 
distance to bregma were evaluated; consecutive sections were treated with 
anti-GFP and either anti-GFAP, anti-Iba1 or anti-Beta III. The 
Haematoxylin and eosin staining was also performed on adjacent sections. 
Sequentially cut sections were finally quantified for the ischemic 
environment, and the NPCs eGFP positive there localized (Figure 2.f2). 
 
 
 
 
Figure 2.f2 Evaluation of the Ischemic regions by Immunofluorescence 
Deparaffinized sections were treated with antibodies to detect Beta III tubulin 
(neurons), GFAP (astroglia) and Iba1 (microglia), for details see the 
Immunofluorescence paragraph. Each analysed area was evaluated by four 
consecutive sections, each of these treated with anti-GFP and an anti-cellular 
marker. The assessment of inflammation (Iba1 positive), glial scar (GFAP 
positive) and neurodegeneration (Beta III positive) areas were used to extrapolate 
the best ischemia estimation, or more simply the average between the areas. In 
the top image there is a section from the same animal treated with Haematoxylin 
and Eosin. All the section were localized at same level.  
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2.7.2.1.1   HAEMATOXYLIN AND EOSIN STAINING  
 
MATERIALS: 
 
Haematoxylin, Sigma-Aldrich 
Eosin, Sigma-Aldrich 
HCl, Sigma-Aldrich 
Ethanol 99.9%, Fisher Scientifics 
Histochoice, Sigma-Aldrich 
 
To deparaffinise sections of tissue, slices were treated for 5 minutes at 
room temperature with Histochoice. The haematoxylin staining was 
incubated on the slides for 5 minutes at room temperature; the tissue was 
rinsed in water and treated with a differentiating solution (0.5%HCl and 
70% Ethanol). After the differentiating solution reaction, the sections were 
rinsed in water and treated for 30 seconds with eosin at room temperature. 
Tissue re-hydration was achieved by bath with increased concentrations of 
Ethanol and finally the coverslips were mounted so that the sample could 
be observed in the microscope. The slices were evaluated with a Zeiss 
Observer D1 light microscope. 
           
         2.7.2.1.2 IMMUNOFLUORESCENCE 
 
SOLUTIONS AND BUFFERS: 
 
PERMEABILIZING SOLUTION:  
 
PBS 
Tween 20   0.5% 
 
BLOCKING SOLUTION: 
 
Permeabilizing solution 
BSA 3% 
 
ANTIBODY SOLUTION: 
 
Permeabilizing solution 
BSA 1% 
 
 
 
76 
 
MATERIALS: 
 
BSA, Sigma-Aldrich 
Tween 20, Sigma-Aldrich 
PBS tablets, Sigma-Aldrich 
Mouse GFP, Abcam 
Rabbit GFP, Invitrogen 
Rabbit DCX, Abcam 
Rabbit GFAP, Dako 
Rabbit beta III, Sigma-Aldrich 
Rabbit Iba1, Wako 
The details regarding the antibodies are described on Table 2.1.t2. 
 
The immunofluorescence was performed on vibratome as well as 
microtome-cut sections. The tissues were permeabilized with the 
permeabilizing solution; 50 µm sections were incubated overnight at 4°C, 
while 12 µm sections were incubated for 30 minutes at room temperature. 
After permeabilization the sections were blocked for one hour with the 
blocking solution, and incubated with the primary antibody previously 
diluted in antibody solution; the reaction was carried out overnight at 4°C.  
 
The day after, the slices were washed 3 times in permeabilizing solution, 
and then the secondary antibody was added to the sections and incubated 
for 1.5 hours at room temperature. After washing out the secondary 
antibody, the coverslips were mounted on the Superfrost Plus slides and 
slices observed under light microscope. 
Vibratome sections were Immunofluorescence processed in a 12 well 
plate, then mounted on the glass slides with coverslips. 
 
The concentrations used for the primary and the secondary antibody 
reactions are described in the following table (Table 2.1.t2). 
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Table 2.1.t2. Primary and secondary antibody concentration used in the 
Immunofluorescence experiment.  
 
 
 
 
 
 
 
Marker Protein Company Prod. # Species Conc. secondary Concentration 
neuron Beta III Sigma-
Aldrich 
T2200 Rabbit 1:500 Alexa 
Fluor, 
dokey-
anti rabbit  
555 
1:700 
glia GFAP Dako Z 0334 Rabbit 1:500 Alexa 
Fluor, 
dokey-anti 
rabbit  555 
1:1000 
neuroblast DCX Abcam Ab18723 Rabbit 1:500 Alexa 
Fluor, 
dokey-anti 
rabbit  555 
1:500 
microglia Iba1 Wako 01919741 Rabbit 1:500 Alexa 
Fluor, 
dokey-anti 
rabbit  555 
1:500 
Transduced 
cells 
GFP Abcam Ab1218 Mouse 1:500 Alexa 
Fluor, 
goat-anti 
mouse 
488 
1:700 
Transduced 
cells 
GFP Abcam Ab6556 Rabbit 1:500 Alexa 
Fluor, 
dokey-
anti rabbit  
555 
1:700 
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2.7.2.1.3 CELL COUNTING   
 
To quantify SVZ neurogenesis occurring in physiological conditions, both 
the OBs were entirely sliced with the microtome and treated with an 
antibody against eGFP. The quantification reflects the actual number of 
eGFP positive cells that migrated to OBs within three weeks of injection. 
 
Quantification in ischemic conditions was estimated by counting the eGFP 
positive cells located in the damaged area. Five regions per brain, situated 
at specific distance points from bregma were quantified: AP +2.5, 1.7, 0, -
1.7, and -3 mm distance to bregma. To evaluate the ischemic environment 
and estimate the number of the migrated SVZ progenitor cells expressing 
eGFP, each of these regions were evaluated by immunofluorescence 
performed on four consecutive sections (10 µm each) located at the 
specified points distance to bregma (AP +2.5, 1.7, 0, -1.7, and -3 mm).  
 
The number of green cells in the ischemic area was first assessed on the 
four consecutive sections (10 µm each) used to analyse the brain region in 
study (AP +2.5, 1.7, 0, -1.7, and -3 mm). The cell density was first 
estimated for each of these regions (40 µm) and in the whole ischemic 
damage.  
 
The total number of green cells in the ischemic environment was then 
estimated by multiplying the density of the green cells in the whole 
damage for the total damage thickness (µm).  
 
2.7.3 STATISTICAL TESTS 
 
 
Batteries of statistical tests were used to analyse behaviour, histology and 
weight rescue. To evaluate the model two parameters were observed: the 
sensorimotor behaviour measured by the 0-28 focal deficit test, and the 
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variation of the body weight. Because the focal deficit assessment is a non-
parametric test, it is not based on a Normal distribution, and so is 
evaluated by the Mann-Whitney rank sum test. The weight variation does 
follow the Normal distribution and is affected by time and treatment. It 
was evaluated by the two-way ANOVA; further analysis at selected time 
points were also evaluated by the Student’s t test. All the cellular and 
infarct volume quantifications were analysed by the un-paired Student’s t 
test and two-way ANOVA. Western Blot analysis and MTT were 
compared by the one-way ANOVA; when a comparison of multiple MOIs 
was involved a two-way ANOVA was used instead. The data correlation 
was performed by a linear regression when both the variables were 
distributed on a Normal curve; for non-parametric data the Spearman’s 
rank Correlation Coefficient was calculated. The survival proportion was 
evaluated by the Gehan-Breslow-Wilcoxon test. This test was selected 
because compared  with  the log-rank (Mantel-Cox) test that gives same 
“weight to deaths” at all-time points, it assigns the score differently 
depending on when the death occurs and for this specific analysis is 
considered more sensitive.  
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  RESULTS 
 
UNDERSTANDING THE IMPORTANCE OF NEUROGENESIS IN 
ISCHEMIC CONDITIONS 
 
The aim of this project is to understand the effect of positive and negative 
modulation of the SVZ’NPCs naturally-occurring post-ischemia. Part 2 of 
the manuscript reports the results to assess the question, and it is divided in 
four main chapters: 
 
1. Development of an efficient cell cycle inhibitor system.  
2. Optimisation of conditions for the long-term study of the Middle 
Cerebral Artery occlusion model. 
3. Evaluation of the efficiency of SVZ-RMS neurogenesis 
stimulation and inhibition in absence of stroke. 
4. Evaluation of the effect of SVZ neurogenesis modulation in 
ischemic conditions. 
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CHAPTER 3 
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3.1 INHIBITION OF CELL CYCLE 
 
SUMMARY  
 
As discussed in Chapter 1, EGF1, EGF2 and IGF1 are widely used in 
research to improve the survival ability of neurons in culture. Moreover 
they are activated during embryogenesis, after stroke, and are also 
involved in cell fate determination and differentiation. The pathway shared 
by these mitogens involves an early binding with a Tyrosine Kinase 
receptor and the activation of a Map Kinase pathway producing the Cyclin 
D1 cytoplasmic accumulation. Last steps concern the Cdk4-CyclinD1 
complex formation, nuclear imports, releases of E2F by the Rb suppressor, 
and activation of the S phase genes (Kornmann, Arber et al. 1998). 
 
In this project the cell cycle arrest was achieved by direct inhibition of the 
Cyclin D1 activity. The goal was accomplished by a LV-based system in 
vitro validated on NIH3t3 fibroblasts. Two different strategies were 
attempted in order to obtain an efficient cell cycle inhibition: the first one 
was intended to block Cyclin D1 activity by cloning a dominant negative 
Cyclin D1 cDNA into a third generation Lentiviral backbone. The plasmid 
was packed into LV and was assessed in vitro. This approach was not 
successful and although much effort was invested to produce the clone and 
to test it in vitro, there was no convincing evidence of an in vitro cell cycle 
inhibition. The second approach we evaluated was based on a second 
generation LV encoding for a shRNA_CyclinD1. The two commercial 
transfer plasmids pGIPZs we tested were designed and cloned by Thermo 
Scientific: pGIPZs_shRNA_CyclinD1_92 (clone 92) and 
pGIPZs_shRNA_CyclinD1_95 (clone 95). Each clone encodes for a 
different hairpin sequence that binds different regions in the CyclinD1 
mRNA. Both plasmids were used to produce LVs and they were evaluated 
in vitro by Cyclin D1 protein down regulation and cell viability assays. 
Although both hairpins were able to make the G1 phase shorter and to 
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induce cellular death, we decided to select clone 92 because vector 
packaging was highly efficient. 
 
During these in vitro investigations we observed a diffuse death phenotype 
already occurring at 24 hours post transduction; according to the literature, 
Cyclin D1 is not just a cell cycle checkpoint factor but it is also involved 
in cellular fate and apoptosis (Han, Ng et al. 1999; Ino and Chiba 2001). 
From the data collected, we concluded the LV_ 
pGIPZs_shRNA_CyclinD1is a valid system to block cellular 
multiplication by either blocking of the G1 phase or apoptosis induction. 
 
3.2 METHODS 
3.2.1 CLONING A DOMINANT NEGATIVE CYCLIN D1 
INTO A THIRD GENERATION LV 
 
pRRLsc_Segfp_CdnCCND1W construct was made using the standard 
cloning procedure described in Chapter 2. The dnCyclin D1 gene sited into 
pFlex_dnCyclinD1 was kindly gifted by Dr. Diehl from Howard Hughes 
Institute, Memphis, and it was inserted into a double expression cassette 
backbone, pRRLsc_Segfp_CNCS1W created by Dr. Yip Ping from Kings 
College London. 
  
The peculiarity of pRRLsc_Segfp_CNCS1W plasmid is the double gene 
expression cassette, where two genes are driven by two different 
promoters, CMV and SFFV. The first cassette is driven by the SFFV 
promoter leading the eGFP expression, while the second cassette contains 
the NCS1 gene under the CMV promoter. The 
pRRLsc_Segfp_CdnCCND1W transfer plasmid produced and used in this 
project was obtained replacing the NCS1 gene with the dnCyclinD1 
sequence. The ability of the mutant to inhibit cell cycle in NIH3t3 cells 
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was previously demonstrated by Diehl and Sherr in 1997 (Diehl and Sherr 
1997). 
 
The cloning strategy was designed using Vector NTI software (Figure 
3.f1); briefly the host backbone was linearized by SpeI digestion (SpeI, 
Promega), then a treatment with Polymerase Klenow was used to blunt the 
ends before a second digestion with XhoI was performed (XhoI, Promega). 
To obtain the excision of the dnCyclinD1 cDNA from the parental 
pFlex_dnCyclinD1, a first cut aimed to linearize the plasmid was obtained 
with BamHI (BamHiI, Promega), followed by a treatment with Polymerase 
Klenow and a second digestion with XhoI. Ligation was performed as 
previously described in Chapter 2; successful cloning was validated by 
diagnostic restriction digests and gel electrophoresis (Figure 3.f1).  
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Figure 3.f1. pRRLsc_Segfp_CdnCND1W lenti backbone. 
 
The map above was elaborated by Vector NTI software and shows the replacement of 
NCS1 gene with the dnCyclin D1 cDNA. On the right is the restriction analysis. Cloning 
was performed by the classical cloning technique; the lentibackbone was introduced into 
Top ten E.Coli cells by heat shock transformation and after DNA extraction the selected 
clone was digested with restriction enzymes.  Expected bands: XhoI 8966 kb, PstI 6739 
kb, 1178 kb, 962 kb, 87 kb, EcoRI 5494 kb, 1924 kb, 1551 kb. 
 
3.2.2 SEQUENCING  
 
The original dnCyclin D1 sequence contains two point mutations 
producing a Threonine conversion in an Alanine in position 156 and 286. 
The substitution in position 156 results in a lack of the ability to form an 
active complex with Cdk4, in turn responsible for the phosphorylation of 
the Rb protein, which heads E2F activation. Moreover, the position 286 is 
a proline-directed phosphorylation site that drives protein ubiquitination 
and degradation; the mutation at this site prevents protein phosphorylation, 
polyubiquitination and stabilizes dnCyclin D1 (Diehl et al 1997). 
 
The pRRLsc_Segfp_CdnCyclinD1 expected sequence was confirmed by 
DNA sequencing techniques performed by Eurofins Mwg/ Operon. In 
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addition, an alignment between dnCyclinD1 and the WT orf isoform was 
made by BLAST in order to ensure the location of the mutation sites 
(Figure 3.f2).  
 
The alignment confirmed the two mutations in position 156 and 286. 
Furthermore, two additional mutations had arisen; a point mutation in 
position 18 responsible for a substitution of a Serine with a Proline, and 
another one in position 160, which changes a Phenylalanine with a 
Leucine (Figure 3.f2). 
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Figure 3.f2. Alignment between mouse dnCyclin D1 (in black) and the 
mouse wt Cyclin D1 (in green).  
 
The alignment shows the two point mutations producing the expected Threonine 
conversion into Alanine (position 156 and 286 on amino acid chain). Two extra 
mutations were identified, causing Serine-18 to be substituted with a Proline, and 
Phenylalanine-160 was substituted with a Leucine. 
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3.3 LV_pRRLsc_Segfp_CdnCND1W IN VITRO 
ASSAYS 
 
pRRLsc_Segfp_CdnCND1W was packed into LV and in vitro tested for  
protein expression and the effect on the cellular multiplication. 
 
As control, we used a second-generation LV carrying and expression 
cassette for eGFP: LV_pHR’SIN-cPPT-SEW. 
 
3.3.1 pRRLsc_Segfp_CdnCND1W: PROTEIN EXPRESSION 
ANALYSIS 
 
Western Blot analysis was done with the assumption that the mutant’s 
amino acid substitutions do not significantly affect the protein size, and 
that the immunoblotting reaction is not sensitive enough to discriminate 
between the endogenous and the exogenous isoforms. Under these 
conditions the translation of the exogenous dnCyclin D1 protein would be 
detectable as a general increase in the cytoplasmic amount of Cyclin D1. 
  
LV_ dnCyclinD1, 1.62 x 108 IU/ml, or control LV_pHR’SIN-cPPT-SEW9 
1.7 x 109 IU/ml, were used to transduce 2 x 105 NIH3t3 cells. The 
transduction conditions were set up in order to achieve MOI 3, 15 and 30. 
Although the blotting analysis revealed a general trend of increasing 
Cyclin D1 protein, especially for MOI 3, the two-way ANOVA did not 
highlight any significant difference between groups (Figure 3.f3). 
 
The cells were harvested at day 8 post-transduction. Higher MOI and 
different harvesting days were also tested with similar results.  
 
 
                                                
9 LV_pHR’SIN-cPPT-SEW, Second generation Lentiviral used as control, it only expresses the 
eGFP gene. 
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a) 
 
 
 
b) 
 
 
 
Figure 3.f3. Cyclin D1 protein variation after LV_dnCyclinD1 
transduction.  
 
NIH3t3 transduction by LV_dnCyclinD1 and LV_ pHR’SIN-cPPT-SEW. Cells 
were transduced at different MOI and harvested at day 8 post-transduction. (a) 
The two green bands in the Western Blot lower panel are both Cyclin D1 and 
they were quantified singularly (CCND1 lower band and CCND1 upper band) as 
well as together (CCND1), part b of the figure. The quantifications were obtained 
comparing the relative Cyclin D1 expression to the endogenous alpha-tubulin. (b) 
The samples were normalized with the mock. Values represent mean ± SEM 
(n=3). No statistical significance using two-way ANOVA was found. 
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3.3.2 LV_pRRLsc_Segfp_CdnCND1W: VIABILITY ASSAY BY 
MTT 
 
 
The ability to induce a blockage of the cell cycle and/or apoptosis was 
evaluated by a viability assay. The test used is based on the colour 
variation of the yellow, water-soluble dye 3 – (4,5-dimethylthiazol-2-yl) 
2,5-diphenyltetrazoliumbromide (MTT) into a blue-violet water insoluble 
formazan. This reaction is partially dependent on the succinate 
dehydrogenase, and it could be used as cellular respiration indicator as 
well as to detect live cells. 
 
LV_dnCyclin D1 (6.6 x 107 IU/ml) and LV_ pHR’SIN-cPPT-SEW (5.10 
x108 IU/ml) were used to transduce 5,000 NIH3t3 cells in a 24 well plate. 
The MTT assay was performed at day 8 post-transduction. 
 
The assay did not detect any significant change in proliferation in the 
LVs_dnCyclin D1 treated NIH3t3 cells, as shown by two-way ANOVA 
(Figure 3.f4). 
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Figure 3.f4. MTT assay for LVs_dnCyclin D1.  
 
The MTT assay was performed with three different MOI (3, 15 and 30) and the 
samples analysed at day 8 post-transduction. Transduced cells were treated with 
MTT for 3 hours at 37°C and crystal formations were left to dry overnight at 
room temperature. The absorbance was read at wavelength 560nm and the 
samples were normalized to the mock. Values represent mean ±SEM (n=3). 
There was no statistical difference in MTT conversion (live cell number) within 
the LVs treated groups, as shown by two-way ANOVA. 
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3.4 CELL CYCLE INHIBITION BY A 
 shRNA_Cyclin D1 
 
The second approach tested was a second-generation LV based system, 
encoding a small hairpin shRNA direct against Cyclin D1 mRNA. The two 
tested hairpins were commercially available from Thermo Scientifics 
(Figure 3.f5) and were packed into a second generation LV. For this 
experiment, the same control used for the pRRLsc_Segfp_CdnCND1W in 
vitro assays was used.  
 
The hairpin sequences were elaborated by Thermo Scientific: 
 
1. Clone pGIPZ_shRNA_640492,  
               Mature sense (5’-3’): ATTGCATGTTCGTGGCCTCTAA 
               Mature antisense (3’-5’): TTAGAGGCCACGAACATGCAAG 
2. Clone pGIPZ_shRNA_640495,  
               Mature sense (5’-3’):  ATGCCACAGATGTGAAGTTCAT 
               Mature antisense (3’-5’): ATGAACTTCACATCTGTGGCAC 
 
 
 
 
 Figure 3.f5. Thermo scientific pGIPZ_shRNAs expression cassette map.  
 
The CMV promoter led the turbo-GFP expression while the IRES is an Internal 
Ribosomal Entry Site for the Puromicin resistance translation. The shRNA is driven by 
the T7-promoter. The WRE or Woodchuck Hepatitis Virus Posttranscriptional is a 
regulatory element that enhances expression of the transgenes. The pUC is the bacterial 
origin of replication, for high copy replication and maintenance in E. coli while the 
AmpR transcription (Ampicillin resistance). The LRTs are the Long Terminal Repeats 
that are important to start the viral reverse-transcription. Ultimately the Sv40 Ori is the 
Simian vacuolating virus 40 origin of replication. 
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2.4.1 DOWN REGULATION OF CYCLIN D1 PROTEIN BY 
shRNA_CYCLIN D1 
 
Cyclin D1 down regulation was evaluated by Western Blot at day 1 post-
transduction in NIH3t3 cells; the method is described in Chapter 2. 
Briefly, NIH3t3 cells were transduced with LVs_shRNA_Cyclin_D1_92 
(5 x 107 IU/ml) or LVs_shRNA_Cyclin D1_95 (9 x 107 IU/ml) or control 
LVs_ shRNA_empty (108 IU/ml). The day after the cells were scraped 
from the plate and the proteins extracted and separated by SDS-page gel 
electrophoresis. After protein transfer to a nitrocellulose membrane the 
immunoblotting was performed. The bands’ relative intensity was 
estimated by Odyssey technology and analysed by one-way Anova. 
 
The analysis was performed in four groups:  
• LV_shRNA_Cyclin_D1_95  
• LV _shRNA_Cyclin_D1_92 
• LV_ pHR’SIN-cPPT-SEW   
• mock.  
After evaluating the best experimental conditions to achieve an efficient 
protein down regulation, MOI 75 was selected as the more effective.   
 
At day 1 post-transduction, cells treated with both the hairpins directed 
against Cyclin D1 drastically reduced cell number and caused extensive 
damage (Figure 3.f6, part a). 
 
The LV_shRNA_Cyclin_D1_95 treated group showed efficient Cyclin D1 
protein down regulation, but it was difficult to pack the transfer plasmid 
into LV (Figure 3.f6). The impossibility of producing a large LV stock did 
not allow for repetition of the experiment for the purpose of statistical 
analysis. 
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Cyclin D1 protein down regulation by clone 92 was repeated in triplicate 
analysed by one-way ANOVA and the Bonferroni’s post hoc test. Cyclin 
D1 protein was statistically significant lower in the samples treated with 
LV_shRNA_Cyclin_D1_92 compared to the group treated with 
LV_pHR’SIN-cPPT-SEW; **p<0.01 by one-way ANOVA (parts b) and c) 
of Figure 3.f6). 
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Figure 3.f6. Western Blot analysis for LVs_shRNA_Cyclin_D1_92 and 
95. 
 
a) Images show the NIH3t3 cells at day 1 post transduction, just prior to 
harvesting. b) Down regulation of Cyclin D1 induced by LV_shRNA_Cyclin D1 
clone 92 (red) and 95 (orange) c) LV_shRNA_Cyclin_D1_92 induced a 
statistically significant Cyclin D1 protein down regulation when compared to the 
LV_ pHR’SIN-cPPT-SEW **p<0.01.  Statistical analysis by one-way 
ANOVA, values represent mean ±SEM (n=3).  
a 
b 
c 
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3.4.2 EFFECT OF CYCLIN D1 DOWN REGULATION ON 
THE CELL CYCLE: CELL VIABILITY BY MTT 
 
NIH3t3 cells were transduced with LV_shRNA_Cyclin_D1_92 (5 x 107 
IU/ml) or LV_shRNA_Cyclin_D1_95 (9 x 107 IU/ml) or LV_ 
shRNA_empty (108 IU/ml). After 24 hours the viability assay was 
performed by MTT, for details see Chapter 2. The experimental conditions 
were planned to achieve MOI 25, 70, 100 and 150, and the data were 
normalized with the mock, analysed by two-way ANOVA and the 
Bonferroni’s post hoc test. Both tested hairpins reduced cell viability 
(reductase level) at MOI 70, whilst at MOI 150 the 
LV_shRNA_Cyclin_D1_92 reduced the reductase level to 60% of the 
level present in the control group, and the LV_shRNA_Cyclin_D1_95 at 
MOI 100 reduced it to 50% of the control group. Metabolically active cells 
were significantly reduced in the LV_shRNA_Cyclin_D1_92 treated 
group at MOI 70, *p<0.05, MOI 100, **p<0.01, and at MOI 150, 
***p<0.001 (a) and b) Figure 3.f7). Metabolically active cells were 
reduced also for the LV_shRNA_Cyclin_D1_95 treated group, for which a 
significant reduction was observed at MOI 70 and 100, ***p<0.001 (c) 
and (d) of Figure 3.f7) 
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Figure 3.f7. Viability assay by MTT, shRNA_Cyclin_D1_92 and 95.  
 
a), c) effect of shRNA_Cyclin D1 on NIH3t3 cells 24 hours post transduction b), 
d) both clones 92 and 95 showed reduced cell viability which was linearly 
dependent on the vector concentration (MOI), *p<0.05, **p<0.01 and 
***p<0.001 for clone 92, and ***p<0.001 for clone 95 (MOI 70 and 100), both 
were compared to the LV_shRNA_Empty. Values represent mean ±SEM (n=3); 
the data were analysed with two-way ANOVA.  
 
 
 
 
 
 
 
a b 
c d 
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3.5 CONCLUSION 
 
The inhibition of the cell cycle was attempted using two LV based 
systems. The first was meant to introduce a dominant negative isoform of 
the Cyclin D1 protein, in turn causing a reduction of the endogenous 
isoform activity and the G1 phase block. Although we found a trend of 
increasing Cyclin D1 protein (as results of the endogenous and exogenous 
protein detection by western blot), especially at MOI 3, we found no 
evidence for the dominant negative activity; possibly a result of the two 
extra mutations that the sequencing pointed out. 
 
The second cell cycle inhibitor system was intended to induce a down-
regulation of the Cyclin D1 mRNA, in turn responsible for a reduction of 
the protein translation and consequently G1 phase blocking. Both hairpins 
in the study produced the Cyclin D1 protein down-regulation with clear 
inhibitory effects on cell cycle and apoptosis. The analysis of protein and 
the cell viability accordingly suggest that the LV_shRNA_Cyclin D1 
system is an efficient tool to block cell cycle in G1. It was repeatedly 
found that Clone 95 was difficult to pack into LVs, and for this reason 
shRNA_CyclinD1_92 was selected for the in vivo studies.  
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CHAPTER 4 
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4.1 MIDDLE CEREBRAL ARTERY OCCLUSION - 
A LONG TERM STUDY 
 
SUMMARY 
 
The use of animals in this study was conducted in agreement with the 
Animals Scientific Procedures Act 1986, and approved in detail by the 
local research ethics committee. 
 
 
The MCAo is the ischemic model we selected to study the effect of 
neurogenesis modulation in post ischemic recovery. 
We can divide this project into two main experiments: 
1. To evaluate the effect of SVZ neurogenesis inhibiting in the post 
ischemic recovery 
2. To evaluate the effect of SVZ neurogenesis enhancing in the post 
ischemic recovery 
The experiments were planned in order to study the effect of the 
treatments across the 30 days following   MCAo. The first milestone in 
achieving these goals was to develop and set up the stroke model. 
 
Ischemic models are quite variable in terms of damage severity and 
survival expectations, and because in this study we planned to combine 
LV intracranial injections with MCAo, the first concern was to find the 
best conditions to have a reliable ischemic model which was robust 
enough to survive and exhibit recovery over 30 days post-ischemia. 
 
The aim of this chapter is to demonstrate the efforts made to develop and 
analyse the MCAo models, so that the best conditions to apply experiment 
1 and 2 as described above can be selected.  
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The MCAo model is a very invasive procedure that produces the 
obstruction of the Middle Cerebral Artery, in turn responsible for extended 
neuronal damage and cell death. The damage severity is closely dependent 
on the duration of the artery occlusion and on the subject’s ability to 
respond to the specific treatment. For the successful experiment, there 
needs to be a good number of ischemic animals which are able to survive 
for long term study; a necessity for a rigorous statistical evaluation of the 
model. Three different variants of the ischemic model were studied: 
pMCAo, 1 hours MCAo (1h_MCAo) and 30 minutes MCAo 
(30’_MCAo).  
 
A high proportion of the deaths as well as the majority of the recovery 
took place during the first ten days after the artery occlusion. The recovery 
curve for tMCAo models covered the first ten days post-surgery, after 
which the majority of the animals acquired an almost normal phenotype. 
The permanent occlusion produced the enduring blood flow interruption 
which was minimally stabilized over time, and the risk of death was high 
across all periods in this case. 
 
4.1.1 ANIMALS 
 
 
C57 Bl/6, male, six to ten week-old were used for the MCAo animals. This 
strain was selected above the others because of its sensitivity to MCAo, 
which is due to the reduced development of Willis’ Circle (Yang, 
Kitagawa et al. 1997). 
 
Post-surgery, the animals were injected daily with glucose-saline until they 
showed ability to feed themselves autonomously. In accordance with the 
UK standard animal cage conditions, a stimulating environment was 
introduced through the use of white tubes in the cage. The animals were 
killed by a transcardial perfusion two weeks after surgery; method 
described in Chapter 2.  
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4.1.2 MODEL EVALUATION 
 
The MCAo animals were evaluated daily for two weeks after the operation 
using the 0-28 focal deficit test described in Chapter 2. After death, the 
ischemic volume was estimated using Haematoxylin and Eosin staining 
described in Chapter 2. To assess the effectiveness of the surgery the 
ischemic animals were compared to the sham. In addition, the difference 
between the effects of the occlusion time was evaluated to highlight the 
most suitable model for long term study. 
 
4.1.2.1 ANIMALS LOST AND EXCLUDED FROM THE ANALYSIS  
 
Thirty-two animals were permanently occluded in the MCA but only four 
survived for two weeks post-surgery. In this group, three brains where lost 
during the cryo-processing. The tMCAo allowed a better survival; ten 
1h_MCAo animals were produced and eight survived, for 30’_MCAo, six 
animals were produced and all of them survived. We assumed all the 
animals died because of the ischemia. 
4.1.2.2 0-28 FOCAL DEFICIT TEST 
 
MCAo induced neurological damage responsible for a post-surgery 
sensory-motor impoverishment. The ischemic outcome is very strong 
during the first 36 hours, where the majority of deaths were also 
concentrated. An improvement was observed across the first ten days, after 
which the phenotype looked very similar to the sham subjects. 
 
All groups presented a strong deficit in the sensorimotor phenotype 
significantly different from the correspondent sham operated animals, as 
shown by the Mann-Whitney rank sum test which gave ****p<0.0001 
(Figure 4.f1). 
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The neurological recovery for the tMCAo models was evaluated by the 
analysis of the mean’s rank Mann-Whitney, and there was no statistical 
difference between the groups (Figure 4.f2).  
 
 
 
 
Figure 4.f1. 0-28 focal deficit test: MCAo groups vs. sham operated 
animals 
The neurological improvement was monitored daily by the 0-28 focal deficit test. 
The test is a battery of sensory-motor tasks, for which, based on the severity of 
damage, a score between 0-4 is assigned. The final score is the sum of the scored 
from each single task. The MCAo behaviour (pMCAo, 1h_MCAo or 30’_MCAo) 
was evaluated in comparison with the sham categories by the mean rank analysis 
Mann-Whitney, with each data point corresponding to the mean rank for the 
group at the specific day after surgery. Each group was individually compared to 
the correspondent sham, and all of them showed a significant post-surgery 
sensory-motor impoverishment, ****p<0.0001, analysis of mean’s rank Mann-
Whitney. pMCAo n =4, 1h_MCAo n =8, 30’_MCAo n=6. 
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Figure 4.f2. 0-28 focal deficit test in the survived population. 1h_MCAo 
vs 30’_MCAo 
 
Neurological improvement post tMCAo. The Mann-Whitney rank sum test did 
not highlight any significant difference in the sensorimotor impoverishment and 
post-surgery recovery produced by 1 hour and 30 minutes of MCA occlusion. 
1h_MCAo n =8, 30’_MCAo n=6, sham n=3. 
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4.1.2.3 WEIGHT RESCUE 
 
A significant body weight variation was observed in all groups after the 
surgery, ****p<0.0001, analysis by the two-way ANOVA. Except for the 
30’_MCAo, no difference between groups was observed. The Bonferroni’s 
post hoc test revealed significant difference between the sham and the 
30’_MCAo at day 2, ***p<0.001, day 3, ****p<0.0001, day 4, ****p<0.0001, 
day 5, ***p<0.001 and day 6, *p<0.05 (Figure 4.f3). 
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Figure 4.f3. Body weight variation  
 
The body weight was expressed as percentage of the pre-operative weight. The 
data were analysed by two-way ANOVA, where the value represents mean ± 
SEM. Although the surgery affected the weight variation in all groups analysed, 
****p<0.000, there was no difference between groups. Only 30’_MCAo group 
was significant different from the control, *p<0.05 by the two-way ANOVA. The 
Bonferroni’s post-hoc test revealed significant difference at day 2, ***p<0.001, 
day 3, ****p<0.0001, day 4, ****p<0.0001, day 5, ***p<0.001 and day 6, 
*p<0.05. pMCAo n =4, 1h_MCAo n =8, 30’_MCAo n=6, sham for pMCAo n=3, 
sham for tMCAo n=3. 
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4.1.2.4 SURVIVAL PROPORTION 
 
After MCAo the number of survivors was drastically reduced. This was 
closely dependent on the occlusion time, which in turn was responsible for 
the severity of the damage. According to the survival curve in Figure 4.f4, 
the occlusion time negatively affected the number of survivors. After the 
permanent occlusion, only 4/32 of animals survived for two weeks post-
surgery, 1 hour occlusion showed 6/10  survivors for the same period of 
time, while  30’_MCAo had a  6/6  survival rate for two weeks. According 
to the survival curve the first week is considered a time where the risk of 
death for both 1h_MCAo and pMCAo is high. There was significantly 
different survival proportion between the pMCAo and 30’_MCAo, 
***p<0.001, and between pMCAo and 1h_MCAo, **p<0.01; moreover, 
the survival fraction was significant different between the pMCAo and the 
sham operated animals, ***p<0.001. The 1h_MCAo group was not 
statistically different from the 30’_MCAo or the sham, analysis by the 
Gehan-Breslow-Wilcoxon Test (Figure 4.f4). 
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Figure 4.f4. Survival curve.  
 
Percentages of survivors post MCAo. pMCAo showed significant different 
survival proportion comparing to 1h_MCAo, **p<0.01, to 30’_MCAo, 
***p<0.001 and the sham group, ***p<0.001, analysis by the Gehan-Breslow-
Wilcoxon Test. pMCAo n=32, 1h_MCAo n=10, 30’_MCAo n=6, sham n=6. 
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4.1.3 INFARCT VOLUME QUANTIFICATION AND DATA 
CORRELATION 
 
MCAo brains were histologically analysed to estimate the ischemic 
volume. The histology of the model depends on the occlusion time and the 
duration of the recovery. Increasing severity of damage was observed in an 
occlusion time-dependent manner, with. the histology of permanent 
MCAo being characterized by a large oedema that extends throughout 
almost the whole ipsilateral hemisphere (Figure 4.f5).  
 
The temporary occlusion was much more variable, with damage in the 
somatosensory cortex, motor cortex, striatum and hippocampus, and is 
often characterized by a variation in the topographic organization of the 
neural network (Figure 4.f6).  Moreover, vacuolation (taken as evidence of 
oedema) was not evident, but extended regions with “accumulation of 
nuclei” visible with the Haematoxylin and Eosin staining (part b) and c) of 
Figure 4.f6) could be observed. 
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Figure 4.f5. Ischemic pMCAo brain.  
 
Ischemic pMCAo brain two weeks after the occlusion of the Middle Cerebral 
Artery. Haematoxylin and Eosin staining in cryo-section. The oedema was 
extended to the ipsilateral hemisphere; at the right bottom of the picture the 
haemorrhagic blood caused by the microcanula insertion. 
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Figure 4.f6. tMCAo brain. 
 
a) Haematoxylin and Eosin staining in microtome cut-sections. 1h_MCAo brain 
two weeks after ischemia b) Detail of the sensory cortex and comparison between 
hemispheres. C) Hyppocampal region in MCAo brain; highlighted the ipsilateral 
region. 
 
 
 
 
 
4.1.3.1 ISCHEMIC VOLUME QUANTIFICATION 
 
 
The ischemic volume was estimated (see Materials and Methods) and 
statistical significance evaluated by one-way ANOVA. For the permanent 
occlusion group three brains were damaged during the cryo cuttings at the 
Cryostat and were not used for the volume quantification. 
a 
b 
c 
 
 
113 
 
 
The brain processing for the temporarily occluded groups was performed 
with a different technique as it was found that the MCAo tissues were not 
easily cut by cryostat; for this reason we decided to embed the brains in 
paraffin and to cut them using a Microtome instead. 
 
The average for the ischemic volume in the 30’_MCAo group (n=6) was 
12.3 mm3 with Std Err=4.5, but, possibly because of the limits of the 
technique used, two subjects did not have a clear ischemic damage and 0 
mm3 was assigned. The damage in 1h_MCAo (n=7) was much more clear 
and extended, with an average of 21.4 mm3. The ischemic volume for the 
pMCAo brain was 57.2 mm3 (Figure 4.f7), and although the variability in 
size and location of the ischemic regions was high, the 1h_MCAo’s 
ischemic volume was significantly higher than the sham operated animals, 
**p<0.01, one-way ANOVA. There was no statistical difference between 
30’_MCAo’s ischemic volume and the sham operated animals (Figure 
4.f7).   
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         Figure 4.f7. Infarct volume quantification.  
 
The infarct volume quantification was estimated performing Haematoxylin and 
Eosin staining on five different brain regions, as described in Chapter 2; the 
ischemic areas were observed and quantified using a Zeiss Observer D1 light 
microscope. Significantly higher ischemic volume for 1h_MCAo, **p<0.01; 
values represent mean ± SEM, by one-way ANOVA. 
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4.1.4 SPEARMAN’S RANK CORRELATION 
COEFFICIENT!
 
The ischemic damage is responsible for the specific neurological 
phenotype raised after surgery. Although there is a clear assumption about 
this correlation, its effectiveness depends on the data acquisition and a 
proper analysis. To evaluate the effectiveness of the systems a Spearman’s 
rank Correlation Coefficient test was performed.  
 
The Spearman’s rank correlation coefficient is a non-parametric test to 
assess the extent to which the relationship between two variables can be 
described by a monotonic function; is the rank of the two variables 
correlated by a well-defined relationship?  
 
The direction and the strength of the correlation is described by the ρ (rho) 
coefficient; for ρ =0 there is no correlation, ρ =1 max positive correlation 
and ρ =-1 maximum negative correlation, or in other words for ρ =±1 the 
variables’ relationships is perfectly described by a monotonic function.   
 
Specifically, the histological data were correlated with the score assigned 
to the behavioural phenotype the day the animals were killed. The 
Spearman’s rank Correlation Coefficient test demonstrated a significant 
correlation between the behaviour at day 14 and the ischemic volume, 
*p<0.05, ρ =0.46 (Figure 4.f8). 
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Figure 4.f8.  Positive correlation between the behavioural score at day 14 
and the ischemic volume quantification 
 
Data were analysed by the Spearman’s rank Correlation Coefficient; each triangle 
corresponds to an animal for which the ischemic volume was correlated to the 
behavioural score assigned at day 14. There was a significant positive correlation 
between the data, *p<0.005, ρ =0.46. 
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4.1.5 CONCLUSION 
 
The MCAo models were produced and evaluated based on the behavioural 
phenotype and the ischemic volume quantification. pMCAo and 
1h_MCAo demonstrated strong ischemic phenotypes which were 
behaviourally and histologically assessed. The 30’_MCAo animals 
demonstrated a clear ischemic phenotype which was statistically different 
from the sham, and presented a smaller ischemic volume, sometimes not 
very different from the sham operated brains.  
 
The analysis of the body weight showed a significant post-operative 
variation in all groups, although difference between groups was 
demonstrated significant only for 30’_MCAo compared to the sham.  
 
There were only 4/32 of pMCAo survivors at day 14 post-surgery; this 
was significantly different comparing to the tMCAo and sham groups, 
**p<0.01 and ***p<0001 by the Gehan-Breslow-Wilcoxon Test.  Because 
of this small fraction of survivors, we decided the pMCAo model was not 
adequate for further experiments. The 1h_MCAo and 30’_MCAo groups 
showed good survival ability and ischemic phenotype, although the second 
one was much milder.  
 
The reduced lesion volume in the 30’_MCAo group was not statistically 
different from the sham, and for this reason was not selected for the 
project’s next step. The 1h_MCAo group demonstrated reasonable 
survival ability and good ischemic phenotype, clearly visible at 
behavioural and histological level.  
 
The effectiveness of the model analysis, by behavioural and histology tests 
was validated by the Spearman’s rank correlation coefficient, *p<0.005, 
ρ=0.46. 
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CHAPTER 5 
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5.1 SVZ-RMS NEUROGENESIS MODULATION IN 
NON-ISCHEMIC CONDITIONS 
 
SUMMARY 
 
Neurogenesis naturally occurs in physiological conditions. The SGZ in the 
hippocampal formation replaces the granular cells of the dentate gyrus 
(DG) over its entire lifetime. Similarly the SVZ on the wall of the lateral 
ventricles controls the replacement of the glomerular and periglomerular 
cells of the OBs (Bovetti, Gribaudo et al.). The tangential migration 
toward the OBs occurs in a well-known pathway by the RMS (Lennington, 
Yang et al. 2003). 
 
As previously discussed, this project is aimed at understanding the 
importance of neurogenesis occurring in ischemic conditions, using LV-
based systems. The efficiency of the LV_shRNA_Cyclin D1 to inhibit the 
cell cycle in vitro, was already demonstrated and discussed in chapter 3.  
 
The systems we selected to boost SVZ neurogenesis were based on 
integration-deficient lentiviral vectors expressing GDNF or TTC from the 
CMV promoter. IDLV_GDNF and IDLV_TTC were produced using 
transfer plasmids produced by Dr. Sherif Ahmed, having already had their 
in vitro effectiveness proven.  
 
1) pRRLcC_TTC_IRESeW  
2) pRRLcC_pGDNF_IRESeW 
 
The peculiarities of these two lentiviral backbones are: i) the expression 
cassette containing a CMV promoter that drives a precursor GDNF or a 
TTC, ii) an internal ribosome entries site (IRES) and iii) a sequence 
encoding for an eGFP. The IRES is a ribosome binding sequence, which 
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allows translation initiation in the middle of a messenger RNA. The 
translation of the eGFP is under control of the IRES activity.  
 
Unfortunately, once the plasmids were packaged into LVs, the IRES 
functionality was fairly low and for this reason we decided for the in vivo 
study to co-inject the IDLV_GDNF and IDLV_TTC with a separate LV 
carrying an eGFP cassette under the SFFV promoter (LV_ pHR’SIN-
cPPT-SEW).  
 
In Chapter 3 I already discussed and demonstrated that 
LV_shRNA_CyclinD1_92 can inhibit cell cycle in vitro in NIH3T3 cells. 
For in vivo experiments, the LV_shRNA_CyclinD1_92 was used in 
combination with LV_ pHR’SIN-cPPT-SEW to inhibit SVZ progenitor 
multiplication, and for long-term cellular detection (14 days). As a control 
another pGIPZ plasmid carrying an empty hairpin (LV_shRNA_Empty) 
was packed into LV, and used in conjunction with the LV_ pHR’SIN-
cPPT-SEW.  
 
GDNF and TTC were packed into IDLVs. These vectors, as discussed in 
Chapter 1, do not integrate the viral DNA in the host genome; rather in a 
mitotic cell population such as the NPCs of the SVZ, the episomal vector 
is expected to be diluted as the cells divide. As the IDLV cassette is lost 
toward the migration, it is assumed that the effect of GDNF or TTC is 
circumscribed within the SVZ area. Because the eGFP cassette is also 
located in the LV_ pHR’SIN-cPPT-SEW, which has the ability to integrate 
the provirus in the host genome, the detection of the SVZ progenitors by 
eGFP expression is ensured over a long time period.  
 
This chapter reports the evaluation of the neurogenesis modulation in 
physiological conditions, based on the injections of the IDLV_ 
pRRLcC_pGDNF_IRESeW, IDLV_ pRRLcC_TTC_IRESeW, 
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LV_shRNA_CyclinD1_92 or LV_shRNA_Empty at the beginning of the 
RMS, in combination with LV_ pHR’SIN-cPPT-SEW for cell marking. 
5.2 METHODS 
 
C57 Bl/6, male, six-ten week old were injected at the beginning of the 
RMS as previously described by Goncalves B. et al. (2008), AP 0.75, ML 
±1.2, DV -1.7. A total of 10 µl of LVs was injected at day zero, 5 µl of 
vector for each hemisphere (LVs were administrated in un-supplemented 
DMEM). Details of the vector batches used in this experiment are shown 
in Table 5.t1.  
 
After the injections the animals were housed in their own cage with 
normal diet and housing conditions. Three weeks later they were killed by 
transcardial perfusion. The tissues were embedded in paraffin by the St 
George’s Histology facility, and immunofluorescence was performed to 
detect and quantify eGFP-positive cells into the OBs; methods described 
in Chapter 2.  
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Table 5.t1. SVZ neurogenesis modulators based on LVs and IDLVs. 
 
The table illustrates the batches used for the in vivo experiment with the related 
titre. IDLV_GDNF and IDLV_TTC due to the lack of the ability of the IRES 
sequence to start the eGFP translation, and the consequential reduction of the 
gene expression were not titrated by flow cytometer.  
 
 
 
 
 
 
123 
 
5.3 HOMOLOGY BETWEEN RAT AND MOUSE 
GDNF 
 
The pRRLcC_pGDNF_IRESeW plasmid used to produce IDLV_GDNF 
encodes a precursor gene from rat. Because our experiments were 
performed in mice, we checked the similarity between mouse and rat 
sequences by a Blast alignment. 
 
Figure 5.f1 presents the results for the Blast alignment between the protein 
sequences: rat GDNF and mouse GDNF. The chain is composed of 199 
amino acids and the identity between the two proteins is 99% (197/199) 
with no gaps.  
 
          
 
 
5.f1 Blast alignment between  mouse GDNF [mus muscolus, GenBank: 
AAB52953.1] and rat GDNF [Rattus norvegicus, GenBank: 
AAM18096.1] 
 
Length=199 
 
Score = 407 bits (1046), Expect = 7e-119, Method: Compositional matrix adjust. 
Identities = 197/199 (99%), Positives = 199/199 (100%), Gaps = 0/199 (0%) 
 
5.4 IDLV_GDNF and IDLV_TTC 
 
The neurogenesis boosting was achieved with a IDLV based system rather 
than the integrative conformation, LV. The integration deficient 
conformation circumscribed the effect of the boosting to the SVZ, as result 
of the cellular proliferation. Moreover because the IDVL_ neurotrophic 
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factor was co-injected with the LV_ pHR’SIN-cPPT-SEW, that carried the 
eGFP cassette, the long-term detection of the NPCs was also possible after 
the migration in the ischemic regions. 
 
5.5 HISTOLOGY AND CELL COUNTING 
 
Three weeks after the injections the animals were killed and 
immunofluorescence labelling was performed to assess effectiveness of 
the injections and to evaluate the efficiency of the SVZ modulator 
systems, based on LVs.   
 
LV_ pHR’SIN-cPPT-SEW in conjunction with the pGIPZs plasmids 
carrying the shRNAs (Figures 5.f1, 5.f2, 5.f3 and 5.f7), or the 
LV_pRRLcC_pGDNF_IRESeW (Figures 5.f4 and 5.f5), or the 
LV_pRRLcC_TTC_IRESeW (Figure 5.f6), was an efficient tool to detect 
SVZ neurogenesis occurring in physiological conditions, to monitor 
migration toward the RMS, and to assess the integration of the neo-born 
neurons into the OBs neuronal network (Figure 5.f7). 
 
Three weeks post injection the LV_shRNA_CyclinD1_92 treated group 
had significantly reduced eGFP positive cells in the OBs, relative either to 
the control group (LV_srRNA_Empty), GDNF and TTC groups (Figure 
5.f2 and Figure 5.f3). Student’s t-test ***p<0.001 (Figure 5.f8). 
 
Under the same conditions, IDLV_GDNF treated group increased the 
number of eGFP positive cells that migrated to the OB, relative to the 
control group (Figure 5.f4 and Figure 5.f5). Student’s t test, *p<0.05, 
(Figure 5.f8). 
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The IDLV_TTC treated group did not exhibit any difference in the number 
of eGFP positive cells migrated to the OBs when compared to the other 
groups (Figure 5.f6 and Figure 5.f8).    
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Figure 5.f1. Migrated eGFP positive cells in the OB: LV_shRNA_Empty 
group. 
 
This animal was injected at the beginning of the RMS with LV_shRNA_Empty 
and LV_ pHR’SIN-cPPT-SEW; the histological analysis was performed three 
weeks later. Anti-mouse eGFP by Abcam (green), nuclear chromatin was 
visualised with DAPI (blue). 
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Figure 5.f2. SVZ-RMS neurogenesis inhibition by LV_shRNA_CyclinD1 
 
Sagittal section of a mouse OBs injected as previous described with 
LV_shRNA_CCND1 and pHR’SIN-cPPT-SEW. Anti-mouse eGFP by Abcam 
(green), nuclear chromatin was visualised with DAPI (blue).  
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Figure 5.f3. SVZ-RMS neurogenesis inhibition by LV_shRNA_CyclinD1 
 
Sagittal section of a mouse OBs injected with LV_shRNA_CCND1 and 
pHR’SIN-cPPT-SEW. Anti-mouse eGFP by Abcam (green), nuclear chromatin 
was visualised with DAPI (blue).  
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Figure 5.f4. SVZ-RMS neurogenesis enhancement by IDLV_GDNF 
 
Animal injected with IDLVs_pRRL_GDNF and pHR’SIN-cPPT-SEW as 
before reported. Anti-mouse eGFP by Abcam (green), nuclear chromatin was 
visualised with DAPI (blue). 
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Figure 5.f5. SVZ-RMS neurogenesis enhancing by IDLV_GDNF 
 
This animal was injected with IDLVs_pRRL_GDNF and pHR’SIN-cPPT-
SEW. Anti-mouse eGFP by Abcam (green), nuclear chromatin was visualised 
with DAPI (blue). 
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Figure 5.f6. SVZ-RMS-OB  migration in an animal treated with LV_ 
pHR’SIN-cPPT-SEW  and LV_pRRLcC_TTC_IRESeW  
 
Animal injected with LVs_pRRL_TTC and pHR’SIN-cPPT-SEW. Anti-mouse 
eGFP by Abcam (green), nuclear chromatin was visualised with DAPI (blue). 
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Figure 5.f7. NPCs derived cells in the OB three weeks after 
LV_shRNA_Empty injection. 
 
Detail of the OB region in a mouse treated with LV_shRNA_Empty and 
pHR’SIN-cPPT-SEW. The histology was performed three weeks later. 
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Figure 5.f8. SVZ’s neurogenesis quantification after lentiviral modulation.  
 
Quantification of the eGFP positive cells migrated into the OBs three 
weeks post intracranial injections of LV vectors. Both the OBs were 
entirely quantified for green labelled cells. Bars represent mean ±SEM. 
The LV_shRNA_CyclinD1 significantly reduced the green cells in the 
OBs, ***p<0.001. Moreover there was a significant increase of eGFP 
positive cells in the OBs as effect of the IDLV_GDNF, when compared to 
the control (LV_shRNA_Empty) group, *p<0.05. Student’s t-test. Data 
from n=3 animals per group.  
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5. 6 CONCLUSION 
                                                                                                                                  
The effectiveness of the SVZ modulator systems based on intracranial LV 
injections was evaluated in absence of stroke. 
 
The animals received 10 µl of vectors divided into two bilateral injections 
at the beginning of the RMS and the histology was performed three weeks 
later. Each group received an LV carrying either the shRNA_CyclinD1 
sequence, the rat precursor GDNF, the TTC or an Empty hairpin, in 
combination with the LV encoding eGFP (LV_ pHR’SIN-cPPT-SEW).  
 
The LVs-eGFP based system was an efficient tool to detect the SVZ 
progenitors and to monitor them along the migration toward the OBs, as 
previously shown by Goncalves et al, 2008. 
 
The SVZ neurogenesis was efficiently inhibited by the LV_ 
shRNA_CyclinD1, ***p<0.001. Moreover the treatment with 
IDLV_GDNF significantly increased the eGFP positive cells into the OBs, 
where *p<0.05, by the Student’s t-test. LV encoding TTC was without 
effect. 
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CHAPTER 6 
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6.1 SVZ-RMS NEUROGENESIS MODULATION IN 
STROKE 
 
SUMMARY 
 
Neurogenesis occurs in ischemic conditions in the SVZ and the SGZ 
(Wang, Zhang et al.; Yamashita, Ninomiya et al. 2006).  It was 
demonstrated that the neuronal precursors can produce not only neurons 
but also glial cell types. Because of the high mobility of microglia, a 
possible origin from the SVZ’s progenitors is still debated (Levison, 
Druckman et al. 2003). 
 
Intrastriatal infusion of GDNF by subcutaneous minipump performed just 
before the ischemia and up to day 7 after MCAo produced GDNF 
diffusion to the SVZ and increased cell proliferation (Kobayashi, Ahlenius 
et al. 2006). In addition, intrastriatal infusion between day 13 and day 23 
post ischemia increased the survival of mature neurons generated after 
MCAo (Kobayashi, Ahlenius et al. 2006).  
 
GDNF can be provided as polypeptide or the gene can be delivered by 
vectors. It was demonstrated that there was a lack of ability of the 
recombinant intracerebral administered GDNF in ALS patients, to provide 
trophic support for the degenerating motor neurons (Deierborg, Soulet et 
al. 2008). This lack of the efficacy could be the result of a poor 
bioavailability of the polypeptide in the mammalian brain. 
 
TTC was demonstrated to be an efficient tool for delivering the mature and 
the recombinant GDNF to the extracellular space, where the growth factor 
can provide trophic support to neighbouring cells (Benn, Ay et al. 2005; 
Li, Chian et al. 2009).  In addition, a recent publication demonstrated that 
a growth factor-like property of TTC compound can positively influence 
 
 
137 
 
degenerating motor neurons in an ALS mouse model (Moreno-Igoa, Calvo 
et al. 2010). 
 
The aims of this chapter are: 
• To compare the effects of negative and positive modulators of SVZ 
proliferation on stroke outcome, in order to assess the importance 
of neurogenesis in ischemic conditions 
• To assess possible protective effects of TTC and GDNF pre-
ischemia administered to the SVZ.  
 
6.2 METHODS  
 
C57 BL/6, male, 6-10 weeks old were injected with 12µl of vector 
suspension. LV was used to deliver the shRNA_CyclinD1 and 
shRNA_Empty while IDLV was used for GDNF and TTC. As described 
in the methods, the SVZ was targeted by two injections performed in each 
hemisphere. The coordinates used were the follow: SVZ_1 AP, 0.25; ML, 
± 0.96, DV -2.75, and SVZ_2, AP, 0.86; ML, ± 0.72, DV -3), as described 
in the methods chapter, the coordinates were estimated based on previous 
experiments, as the regions with the major probability to develop an 
ischemic lesion after 1h_MCAo.  
 
In this experiment four different groups of mice were investigated (n=10 
per group);  
i) SVZ neurogenesis inhibition by LV_shRNA_CyclinD1,  
ii) SVZ neurogenesis boosting by IDLV_GDNF, 
iii) SVZ neurogenesis boosting by IDLV_TTC, 
iv) LV_shRNA_Empty (control). 
All vectors were co-injected with the LV_ pHR’SIN-cPPT-SEW that 
carried an eGFP cassette. Except for the LV_shRNA_CyclinD1_92, the 
batches used in this experiment were the same as used for the experiment 
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described in Chapter 5.  The information about batches and titres used is 
illustrated in Table 6.f1. 
 
After the intracerebral injections the animals were returned to their own 
cage with food and water ad libitum. Animals were monitored daily for 
unexpected adverse effects and signs of distress, weighed to monitor post-
surgical recovery; animals underwent 1 hour MCAo at day 14 after 
intracerebral injections. In all cases weight had returned to pre-injection 
level. After the ischemia induction the animals were closely monitored for 
their weight and the temperature, and it was ensured that their conditions 
were not beyond the humane limits set for termination. During the first 2-4 
days the animals were left in a warm cage and glucose-saline was 
intraperitoneally administered.  
 
After MCAo animals’ recovery was followed daily for 30 days by the 0-28 
focal deficit test. They were killed by transcardial perfusion and the brains 
were analysed by immunofluorescence and Haematoxylin and Eosin 
staining as described in Chapter 2.  
 
The experiment was conducted blind; the groups were named as A, B, C 
and D to identify the injections (respectively LV_shRNA_CyclinD1, 
LV_shRNA_Empty, IDLV_GDNF and IDLV_TTC). All histological 
analysis was carried out by myself on this coded material. Only after the 
histology was completed and the green cell numbers and ischemic volume 
quantified, the treatment performed in each group was revealed, and data 
pooled.  
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Table 6.f1. LVs and IDLVs used in the experiment with the related titre. 
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6.3 ANIMALS LOST AND EXCLUDED FROM THE 
ANALYSIS 
 
10 animals per group were investigated, two of them died because of the 
effect of the anaesthesia during the 1h_MCAo. A total of 21 animals 
across all groups died after the ischemia.  
 
1 brain injected with the IDLV_TTC was not properly processed with 
paraffin, and it was not possible to perform the histological evaluation.  
 
1 animal from the LV_shRNA_Empty was excluded from the analysis 
because the behaviour and the histology data deviated from the group’s 
means by more than 2 standard deviations (Chauvenet's criterion).  
 
6.4 HISTOLOGY  
 
6.4.1 POSITIVE CONTROL: SVZ-DERIVED NEURONAL 
PROGENITOR CELLS IN THE OLFACTORY BULBS  
 
As discussed in Chapter 2, injection coordinates were decided based on 
previous experiments. SVZ regions close to the focus of ischemic damage 
produced by 1h_ MCAo were selected.  
 
To demonstrate effectiveness of the injections and long-term detection of 
the NPCs, the OBs were examined to identify eGFP positive cells, 
assumed to have migrated from the neurogenic islands of the SVZ (Figure 
6.f1 and Figure 6.f2).  
 
eGFP positive cells were found in the intrabulbar part of the anterior 
commissure (aci) and in the granular cell layer of the OB (GrO), (Figure 
6.f1). 
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Under the same conditions, and to demonstrate effectiveness of the SVZ 
neurogenesis inhibition, the OBs of the animals treated with the 
LV_shRNA_CyclinD1 were analysed, and compared to the other groups. 
LV_shRNA_CyclinD1 efficiently inhibited neurogenesis as demonstrated 
by the absence of eGFP positive cells in the OB (Figure 6.f2). 
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Figure 6.f1. Positive control: eGFP positive cells migrated into the OBs  
 
OBs of an MCAo animal pretreated with IDLV_GDNF and and LV_ pHR’SIN-
cPPT-SEW. The eGFP positive cells localized within the aci and GrO at 2.80 mm 
anterior from bregma, top picture. The histology was performed 30 days after 
reperfusion by Immunofluorescence; co-staining anti-GFP, (green), and anti-
rabbit GFAP antibody (red)). 
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Figure 6.f2. Positive control: effect of the inhibition of the SVZ 
neurogenesis in the OBs  
 
Animal injected with LVs_shRNA_Cyclin D1/LV_ pHR’SIN-cPPT-SEW and 
underwent to MCAo two weeks later; the OBs region is highlighted. The eGFP 
positive cells localized within the aci and GrO at 2.80 mm anterior from bregma, 
top picture. Histology performed by Immunofluorescence; co-staining mouse 
anti-GFP (Abcam) and rabbit anti-GFAP (Dako).  
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6.4.2 EFFECT OF MCAo ONE MONTH AFTER: THE 
ISCHEMIC BRAIN 
 
Transient focal ischemia (1h_MCAo) induced migration of NPCs in the 
ipsilateral ischemic area. The neuronal progenitors were found along the 
anterior part of the anterior commissure (aca) and surrounding the lateral 
ventricle (lv) in the ipsilateral hemisphere; some cells extended to the 
caudate putamen (CPu) already in the forebrain at 1.70 mm anterior from 
bregma, (Figure 6.f3). Only a few eGFP positive cells co-expressed a 
marker for differentiated cell types (Iba1, DCX, or GFAP).  
 
eGFP positive cells were found in the CPu: the migrated cells were found 
at 1.17 mm from the ventricles, and some of them looked differentiated, 
but  they were not positive for any of the cellular markers tested (GFAP, 
Iba1, Beta III and DCX), Figure 6.f4. 
 
The ipsilateral SVZ (i.e. ipsilateral to the focal ischemic lesion) but not the 
contralateral was found expanded with an increase of the eGFP positive 
cells (Figure 6.f5 and Figure 6.f6). In addition, some eGFP-labeled cells 
grouped like neurogenic islands were found in the ischemic cortex and 
striatum (Figure 6.f6 and Figure 6.f7). In the cortex the eGFP positive cells 
were found at 1.87 mm from the SVZ (Figure 6.f7). 
 
eGFP positive cells were repeatedly found in white matter tracts (the aca, 
and the corpus callosum; Figure 6.f8 and Figure 6.f9). As previous authors 
suggested, MCAo induced an increase in cell number in these regions 
(Gotts and Chesselet 2005). Moreover, the ipsilateral SVZ expansion 
presented in Figure 6.f9 suggests a possible migratory pathway between 
the SVZ and the aca. 
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Figure 6.f3. MCAo-induced migration of NPCs to the lesion areas. 
 
eGFP positive cells in ischemic striatal regions. In the above images an animal 
was injected with a mix of IDLV_GDNF and LV_ pHR’SIN-cPPT-SEW close to 
the wall of the lateral ventricles and two weeks later underwent to 1h_MCAo. 
The histology was performed by Immunofluorescence; sequentially cut sections 
were treated with a mouse anti-eGFP (Abcam) and a cellular marker to detect 
microglia (rabbit anti-Iba1, Wako), glia (rabbit anti-GFAP, Dako), neurons and 
neuroblasts (rabbit anti-Beta III, Sigma-Aldrich and rabbit anti-DCX, Abcam). 
The eGFP positive cells were found in the aca and CPu, as described by the top 
map, AP 1.70 mm from bregma. Brain map taken from The Brain Mouse Atlas 
by Franklyn and Paxinos. 
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Figure 6.f4. eGFP positive cells in the ischemic striatal region. 
 
The animals were injected close to the wall of the lateral ventricles with a) 
IDLV_TTC and LV_ pHR’SIN-cPPT-SEW b) IDLV_GDNF and LV_ pHR’SIN-
cPPT-SEW. Two weeks later they were subjected to 1h_MCAo. The 
immunostaining was performed with a mouse anti-eGFP (Invitrogen) and 
alternatively a rabbit anti-Beta III (Sigma-Aldrich), or a rabbit anti-GFAP 
(Dako). Region locxalized at AP 1.18 mm from bregma. Brain map taken from 
The Brain Mouse Atlas by Franklyn and Paxinos. 
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Figure 6.f5. Increase in eGFP expressing cells in the ipsilateral SVZ and 
aca 
 
The pictures above derived from an animal treated with IDLV_GDNF/ 
LV_pHR’SIN-cPPT-SEW and consequently subjected to 1h_MCAo; eGFP 
positive cells localized in the ipsilateral SVZ and aca.  The immunofluorescence 
staining was performed with a mouse anti-eGFP (Invitrogen) and a rabbit anti-
Iba1 from (Wako). Section located at AP 0.74 mm from bregma. Brain map taken 
from The Brain Mouse Atlas by Franklyn and Paxinos. 
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Figure 6.f6 eGFP and DCX positive niche like structure in the ischemic 
striatum.  
 
Expansion of the SVZ region in MCAo brain; the neurogenic area was positive 
for DCX, moreover groups of progenitor cells expressing DCX were found in the 
closer striatum. The animal was injected on the wall of the lateral ventricles with 
IDLV_TTC /LV_ pHR’SIN-cPPT-SEW and two weeks later subjected to 
1h_MCAo. The histology was performed by Immunofluorescence; mouse anti-
eGFP (Invitrogen) and a rabbit anti-Iba1 (Wako). The section was localized at AP 
0.74 mm from bregma.  
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Figure 6.f7. eGFP positive niche like structure in the ischemic cortex. 
 
EGFP positive cells localized in the sensory cortex after ischemia. The animal 
was injected on the wall of the lateral ventricles with IDLV_GDNF and LV_ 
pHR’SIN-cPPT-SEW; after two weeks it was subjected to 1h_MCAo. The 
histology was performed by co-staining with mouse anti-eGFP (Invitrogen) and 
rabbit anti-Beta III (Sigma-Aldrich). The eGFP positive cells were at 1.87 mm 
from the closer SVZ; AP 0.74 mm distance from bregma. 
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Figure 6.f8 EGFP positive cells localized within the corpus callosum 
 
 
EGFP positive cells localized within the corpus callosum: some of them co-
expressed GFAP. The animals were injected on the wall of the lateral ventricles 
with LV_shRNA_Empty/LV_ pHR’SIN-cPPT-SEW a) and IDLV_TTC 
/LV_pHR’SIN-cPPT-SEW b), after two weeks underwent 1h_MCAo. The 
histology was performed by Immunofluorescence; mouse anti- eGFP (Invitrogen) 
and alternatively a rabbit anti-Beta III (Sigma-Aldrich) or a rabbit anti-GFAP 
(Dako). The sections were localized at AP 1.18 mm from bregma. 
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Figure 6.f9. Possible radial migration pathway SVZ-aca 
 
Neural progenitors were localized along the SVZ with an enlargement visible at 
the ventral side; the DCX positive cells as well as eGFP positive cells were 
located within and surrounding the aca. The animals were injected on the wall of 
the lateral ventricles with a) IDLV_ GDNF/LV_pHR’SIN-cPPT-SEW or b) 
IDLV_TTC/LV_pHR’SIN-cPPT-SEW and two weeks later they were subjected 
to 1h_MCAo. Immunostaining was performed with a mouse anti-GFP with 
alternatively a rabbit anti-Beta III (Sigma-Aldrich) or a rabbit anti-DCX  
(Abcam). AP 1.18 mm from bregma. 
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6.4.3 EVALUATION OF THE ISCHEMIC ENVIRONMENT 
 
The ischemic volume was evaluated by Haematoxylin and Eosin staining 
and Immunofluorescence techniques. As described in Chapter 2, the 
quantification by Haematoxylin and Eosin alone was not sensitive enough 
to detect the ischemic environment in one-month reperfusion brains. For 
this reason, flanking the classical histology, neurodegeneration, glial scar 
and inflammation process were evaluated by Immunofluorescence.  
 
The ischemic environment is composed of degenerating neurons, glial scar 
and activated microglia, with each of these variables changing with time 
and the brain restoration. The localization and quantification of the 
ischemic damage by one of these parameters alone would give only a 
partial view of the damage. For this reason the average volume between 
the glial scar, the inflammation and the neurodegeneration was performed 
and evaluated as the best estimation of the ischemia.  
 
IDLV_GDNF as well as the IDLV_TTC treated groups, showed 
significant increase of the inflammation volume compared to the control, 
*p<0.05, Student’s t test (Figure 6.f10). Diversely, the volume of the glial 
scar and the volume occupied by degenerating neurons (ischemic core) 
was the same when the groups were compared (Figure 6.f11 and Figure 
6.f12).  
 
The ischemic volume was estimated to be between 5 and 15 mm3 with no 
difference between groups (Figure 6.f13). 
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Figure 6.f10. Volume quantification of the regions covered by activated 
microglia. 
 
Estimation of the inflammation reaction after ischemia. The analysis was 
accomplished by detecting Iba1 expressing cells using a rabbit anti-Iba1 antibody 
(Wako). The Student’s t test pointed out an increase of the inflammation process 
in the IDLV_GDNF and IDLV_TTC treated groups, *p<0.05; values represent 
mean ± SEM. LV_shRNA_Cyclin D1 n=3, LV_shRNA_Empty n=3, 
IDLV_GDNF n=7 and IDLV_TTC n=4. 
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Figure 6.f11. Glial scar quantification 
 
Estimation of the glia scar formation after ischemia. The analysis was 
performed by quantification of the volume covered by GFAP expressing 
cells. No variation was detected in the groups under analysis. In the plot the 
values represent mean ± SEM; analysis by the Student’s t test. 
LV_shRNA_Cyclin D1 n=3, LV_shRNA_Empty n=3, IDLV_GDNF n=7 
and IDLV_TTC n=4. 
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Figure 6.f12. Quantification of the neurodegenerative regions.  
 
Estimation of the core region (neurodegeneration) after ischemia. The analysis 
was performed by quantification of the volume where Beta III was under 
expressed. No variation was detected in the groups under analysis. The analysis 
was accomplished using a rabbit anti-Beta III antibody (Sigma-Aldrich). In the 
plot the values represent mean ± SEM; analysis by the Student’s t test. 
LV_shRNA_Cyclin D1 n=3, LV_shRNA_Empty n=3, IDLV_GDNF n=7 and 
IDLV_TTC n=4. 
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Figure 6.f13. Infarct volume quantification. 
 
The ischemic volume quantification was estimated as the average between 
the volume of neurodegeneration (down-regulation of Beta III), glial scar 
(up-regulation of GFAP or activated astrocytes) and the inflammation (up-
regulation of Iba1 or activated microglia). There was no difference in the 
ischemic volume produced after 1h_MCAo. Values represent mean ± SEM; 
analysis by the Student’s t test. LV_shRNA_Cyclin D1 n=3, 
LV_shRNA_Empty n=3, IDLV_GDNF n=7 and IDLV_TTC n=4.  
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           6.4.4   eGFP-POSITIVE CELLS IN THE ISCHEMIC AREA 
 
eGFP positive cells were counted in the ischemic regions after 30 days of 
reperfusion. The counting was performed in 5 regions per brain, that were 
identified at specific position from bregma:  AP +2.5, 1.7, 0, -1.7, and -3 
mm. As described in Chapter 2, for each of these regions (AP +2.5, 1.7, 0, 
-1.7, and -3 mm) four consecutive sections were co-stained with a mouse 
anti- eGFP from Sigma-Aldrich and a specific cellular marker (rabbit anti-
Iba1 from Wako, rabbit anti-GDNF from Dako, rabbit anti-Beta III from 
Invitrogen and rabbit anti-DCX by Abcam). The estimation of total 
number of green cells in the ischemic volume is described in the Chapter 
2.   
 
The injection of the LV_shRNA_CyclinD1in the SVZ efficiently reduced 
the number of eGFP positive cells in the ischemic environment, **p<0.01, 
Student’s t test (Figure 6.f14).  
 
The injection of the IDLV_GDNF in the SVZ increased the eGFP positive 
cells in the MCAo brains, *p<0.05, Student’s test (Figure 6.f15).  
 
Due to high variability between subjects, the IDLV_TTC treated group did 
not show any significant variation of the eGFP positive cells migrated to 
the ischemic areas (Figure 6.f16).  
 
The characterization of the phenotype for the eGFP expressing cells did 
not point out a predominant phenotype (Figure 6.f17). One month post 
MCAo, the neural progenitors born in the SVZ and migrated in the 
ischemic boundaries, were for the most part not positive for any of the 
cellular markers tested.  
 
There were no convincing eGFP positive cells co-expressing Beta III 
(Figure 6.f17). As many papers reported neurodegeneration occurs very 
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early after the differentiation; Lindvall and Kokaia (2004) described the 
80% of the stroke-generated neurons died during the first 14 days post 
ischemia (Lindvall and Kokaia 2004). Moreover, a diffuse expression of 
lipofuscin in dying and dead cells did not allow sure discrimination 
between the eGFP and lipofuscin. Regarding the remaining markers: 
GFAP was 0.31% of the total green cells, while Iba1 0.29% and DCX 
0.33%. (Figure 6.f17). 
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Figure 6.f14 eGFP positive cells in the ischemic area: 
LV_shRNA_CyclinD1 group.  
 
Quantification of eGFP positive cells in ischemic region; group treated with 
LV_shRNA_Cyclin D1 and  LV_ pHR’SIN-cPPT-SEW. The animals 
treated with LV_shRNA_CyclinD1 drastically reduced the number of eGFP 
positive cells estimated within the ischemic regions, **p<0.01. Values 
represent mean ±SEM; Student’s t test.  
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Figure 6.f15. eGFP positive cells in the ischemic area: IDLV_GDNF 
injected group. 
 
MCAo group treated with IDLV_GDNF and  LV_ pHR’SIN-cPPT-SEW. 
IDLV_GDNF increased the number of eGFP positive cells within the ischemic 
regions *p<0.05. Values represent mean ±SEM; Student’s t test. 
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Figure 6.f16. eGFP positive cells in the ischemic area: IDLV_ TTC 
injected group. 
 
Quantification of eGFP positive cells within the ischemic region; group treated 
with IDLV_TTC and  LV_ pHR’SIN-cPPT-SEW. The number of eGFP positive 
cells estimated in the ischemic boundaries was not statistically different from the 
control. Values represent mean ±SEM; p=0.42, Student’s t test. 
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Figure 6.f17. Analysis of phenotype in the eGFP positive cells migrated to 
the ischemic environment. 
 
The eGFP positive cells localized in the ischemic region where evaluated for the 
phenotype by Immunofluorescence. 99.07% of the eGFP positive cells did not 
co-express any of the marker assessed (Iba1, Beta III, GFAP, DCX). 
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6.4.5 IDLV_GDNF INJECTION IN THE SVZ IMPROVED 
THE NATURAL RESPONSE TO ISCHEMIA. !
 
Ischemia-induced proliferation of neural progenitors has been extensively 
demonstrated (Le Magueresse, Alfonso et al.; Sugiura, Kitagawa et al. 
2005; Yamashita, Ninomiya et al. 2006). The quiescent NPC population 
responds to stimuli released by the ischemic environment. With the 
hypothesis of a linear relationship between the damage severity and SVZ 
response, the correlation between the ischemic damage and eGFP positive 
cells located there was analysed by linear regression.  
 
Although the relationship was not statistically significant in the control 
group (R10=0.19), the IDLV_GDNF significantly improved it with 
*p<0.05 and R=0.68, as proved by the linear regression analysis.  The 
treatment with the LV_shRNA_CyclinD1 reduced the coefficient to 
0<R<0.005. The linear regression analysis for the IDLV_TTC group was 
not statistically significant where R= 0.16 (Figure 6.f18). 
 
The linear relationship between the green cells migrated in the ischemic 
regions and the volume (or damage severity) was further analysed by 
possible correlation between green cells and glial scar, green cells and 
inflammation or green cells and neurodegeneration. Although there was no 
linear relationships between the green cells and glial scar or inflammation, 
the neurodegeneration volume (or core volume) was highly associated 
with the number of migrated NPCs in the ischemic regions, ***p<0.001 
and R=0.92, Linear Regression analysis (Figure 6.f19). 
 
 
                                                
10 R is the correlation coefficient and is a measure of the goodness of fit of the linear regression. 
It can vary between 0 and 1; 0 when there is no linear relationships between the variables X and 
Y, while for R=1 there is a perfect distribution of the X on the line, in turn this allow a complete 
predictability of the Y values knowing the related X.    
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Figure 6.f18. The IDLV_GDNF increased the neurogenic response to 
ischemia.  
 
1h_MCAo induced neurogenesis of the SVZ in a damage-severity dependent 
manner. The treatment with the IDLV_GDNF boosted the SVZ response, 
*p<0.05, by the Linear Regression analysis. The R values highlighted an increase 
in the linear relationships between the damage severity and the neurogenesis of 
the SVZ. IDLV_GDNF R=0.68, LV_shRNA_Empty R=0.1, IDLV_TTC R=0.16 
and LV_shRNA_CyclinD1 0<R<0.005 
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Figure 6.f19. Linear regression analysis of the ischemic volume and the 
eGFP positive cells located there: IDLV_GDNF injected group. 
 
The linear regression analysis was performed to evaluate which part of the 
ischemic environment had influenced most the neurogenesis of the SVZ. There 
was no linear relationships between the number of eGFP positive cells and the 
glial scar, as well as the inflammation process; conversely the neurodegeneration 
affected the response of the SVZ the most with ***p<0.001 and R=0.92 
estimated by linear regression analysis.  
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6.4.6 LV_shRNA_CyclinD1 REDUCED RECOVERY 
ABILITY AFTER MCAo!
 
The neurological damage was evaluated on a daily basis by the 0-28 focal 
deficit test described in Chapter 2.  
 
The analysis of the survivors11 treated with the LV_shRNA_CyclinD1 
showed a significant reduced recovery ability during the first two weeks 
post ischemia, as demonstrated by the Mann-Whitney rank sum test that 
gave *p<0.05 (Figure 6.f20). After day 14, the animals’ behaviour was 
very similar to the LV_shRNA_Empty (control group).  
 
LV_shRNA_CyclinD1 drastically increased the frequency of death during 
the first five days post ischemia, with 5 out 9 subjects suffering this fate 
(Figure 6.f21). 
 
The analysis of the variation of the body weight did not show difference in 
the groups after the intracranial injections (part a) of Figure 6.f22). A trend 
to delayed recovery of pre-operative weight was visible in the 
LV_shRNA_CyclinD1 group after 1h_MCAo (part b) of Figure 6.f22). 
Moreover, day 3 after 1h_MCAo was further analysed by the Student’s t 
test that demonstrated a statistically reduced body weight with *p<0.001 
(part c) of Figure 6.f22) 
 
 
 
 
 
 
                                                
11 The survivors (or survival population) are the ischemic animals that were able to survive for 
30 days after 1h_MCAo 
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Figure 6.f20. Neurological recovery in the surviving populations: effect of 
LV_shRNA_CyclinD1 after 1h_MCAo 
 
The neurological improvement was assessed on a daily basis by the 0-28 focal deficit 
test. LV_shRNA_CyclinD1 group showed a significant increase in the ischemic 
sensory-motor phenotype rose after ischemia, *p<0.05, Mann-Whitney rank sum test. 
Values represent the median of the score assigned. For the LV_shRNA_CyclinD1 group 
n=3, and for the LV_shRNA_Empty group n=3. One animal treated with the Empty 
hairpin was excluded from the analysis because it was greater than 2 standard deviations 
from the mean, Chauvenet's criterion. 
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Figure 6.f21 LV_shRNA_CyclinD1 increased the number of deaths during 
the first 5 days post ischemia.  
 
LV_shRNA_Cyclin D1 group reduced the number of survivors after ischemia. 
The curves were analysed in pair by the Gehan-Breslow-Wilcoxon.  
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Figure 6.f22. Body weight variation after surgical procedures: 
LV_shRNA_CyclinD1 injected group. 
 
Analysis of the variation of the body weight in the survival populations. There 
was no difference in the groups after the intracranial injections (part a) of the 
picture), although after 1h_MCAo there was a trend to delay the weight rescue 
for the LV_shRNA_Cyclin D1 injected group (part b) of the picture). Values 
represent mean ± SEM; analysis by the two-way ANOVA.  The variation of the 
body weight was significantly different at day 3 post 1h_MCAo, *p<0.005; 
analysis by the Student’s t test (part c) of the picture). For the 
LV_shRNA_CyclinD1 group n=3, and for the LV_shRNA_Empty group n=3.  
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6.4.7 TREND TOWARDS IMPROVED NEUROLOGICAL 
RECOVERY IN IDLV_GDNF AND IDLV_TTC 
 
Post ischemic neurological improvement was assessed as previously 
described in Chapter 2.   
 
From a first analysis of survivors both the IDLVs treated groups, GDNF 
and TTC, presented a reduction of the post-operation neurological 
improvement compared to the control (Figure 6.f23). The neurological 
improvement was analysed by the Mann-Whitney rank sum test that 
demonstrated a statistically reduction of the sensorimotor recovery after 
1h_MCAo; ***p<0.001 for IDLV_TTC and ** for IDLV_GDNF, both 
compared to the control group. 
 
After a detailed analysis of the subjects, a trend of surviving and of 
proportionally reducing damage was associated with the growth factor 
treated groups, especially for IDLV_GDNF. Because the control group 
lost many animals with a severe and intermediate ischemia, only mildly 
affected subjects were able to survive until day 30 post MCAo, while the 
survivors of the growth factors treated groups also comprised subjects with 
an intermediate stroke.  In such circumstances the groups under 
comparison are extremely diverged in terms of stroke severity, in turn 
affecting the response to the treatments and the following statistical 
analysis. 
 
To avoid a misleading data analysis due to an imbalance between the 
control and the growth factor-treated groups, the first five days were 
considered to have a bigger population with similar characteristics to 
compare. The analysis of the subjects alive at least until day 5 post 
1h_MCAo showed a trend of improving neurological outcome after 
ischemia, for both the IDLV_GDNF and IDLV_TTC treated groups 
(Figure 6.f24 and Figure 6.f25). This trend for IDLV_GDNF injected 
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group was associated to p=0.065 by the Mann-Whitney rank sum test 
(Figure 6.f24). 
 
Figure 6.f26 shows the entire data set of the neurological recovery for the 
MCAo animals under analysis. From the plots is possible to evaluate the 
MCAo effect on the sensorimotor behaviour across the first 7 post-
operative days. The treatment with the IDLV_GDNF tended to reduce the 
severity of the ischemia, as shown by the reduced average and lower 
variability for the 0-28 focal deficit score. Moreover, the intermediate 
ischemic subjects that had been treated with the IDLV_GDNF survived 
longer compared to the other subjects with the same ischemic severity but 
that received a different treatment, Figure 6.f26. 
 
The analysis of the body weight did not highlight any difference after the 
intracranial injections for the IDLV_GDNF and IDLV_TTC groups, 
although the body weight tended to be lower in the IDLV_TTC injected 
group (part a) of Figure 6.f27). In addition, after 1h_MCAo these groups 
showed a trend towards reduced post-operation weight, both in 
comparison with the control group (part b) and c) of Figure 6.f27); the 
analysis was performed by the two-way ANOVA. Day 3 and 4 were 
further analysed by the Student’s t test that demonstrated a significant 
reduction of the body weight of the IDLV_GDNF treated group compared 
to the control, **p<0.01 (part d) and e) of Figure 6.f27). 
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Figure 6.f23. Paradox of the neurological deterioration in the growth 
factor-treated groups: effect of IDLV_GDNF and IDLV_TTC. 
 
Analysis of the animals survived for 30 days after 1h_MCAo. Neurological 
improvement was assessed on a daily basis by the 0-28 focal deficit test. There 
was a paradoxical increased of the ischemic phenotype for the growth factors 
treated groups. The curves were analysed by the Mann-Whitney rank sum test 
that assigned **p<0.001 for the difference between the LV_shRNA_Empty and 
the IDLV_GDNF; while ***p<0.0001 for the LV_shRNA_Empty and the 
IDLV_TTC. Values represent the mean of the ranks at specific time points after 
1h_MCAo. For the LV_shRNA_Empty group n=3, for the IDLV_GDNF group 
n=7 and for the IDLV_TTC group n=5.  
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Figure 6.f24. Neurological recovery during the first five days after 
1h_MCAo: IDLV_GDNF injected group. 
 
Evaluation of the ischemic phenotype for subjects survived until day 5 post 
surgery. The analysis revealed a trend of improving the sensory-motor 
performance in the IDLV_GDNF treated group. Values represent the rank’s 
mean, p=0.065, Mann-Whitney rank sum test. LV_shRNA_Empty group n=7, 
IDLV_GDNF n=9 
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Figure 6.f25. Neurological recovery during the first five days after 
1h_MCAo: IDLV_TTC injected group. 
 
Evaluation of the ischemic phenotype for subjects surviving until day 5 post 
surgery. The analysis revealed a trend of improving the sensory-motor 
performance in the IDLV_TTC treated group. Values represent the rank’s mean, 
p=0.11, Mann-Whitney rank sum test. LV_shRNA_Empty group n=7, 
IDLV_TTC n=6 
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Figure 6.f26. 0-28 Focal deficit test dot plots evaluation. 
 
The plots above show how the developing over time of the ischemic phenotype 
after 1h_MCAo; this was evaluated on the survival fraction by the 0-28 focal 
deficit test. The plots were analysed by the Mann-Whitney rank sum test but not 
difference between groups was found statistically significant at any time point.  
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Figure 6.f27. Body weight variation after surgical procedures: 
IDLV_pRRL GDNF and IDLV_pRRL TTC injected groups. 
 
There was no difference in weight variation developed after intracranial 
injections. In addition, no statistically different body weight variation was 
observed after 1h MCAo, even though a trend of reduced weight gain occurring 
post-operation was evident in both groups  (b) and c) of the picture). Values 
represent mean ± SEM; analysis by the two-way ANOVA. The IDLV_GDNF 
treated group was further analysed at post-operational day 3 and 4 by the 
Student’s t test; statistically significant body weight reduction in the animals 
treated with the IDLV_GDNF either at day 3 and 4 after 1h_MCAo, **p<0.01 
(part d ) and e) of the picture). For the IDLV_GDNF group n=7, for the 
IDLV_TTC n=5 and for the LV_shRNA_Empty group n=3.  
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6.4.8 SURVIVAL PROPORTION  
 
Although a large proportion of subjects died across the experiment 
because of the ischemia, the LVs treated groups tended to deviate from the 
expected number of deaths depending on the treatment received. 
 
Only 40% of subjects in the control group survived the experiment (30 
days post 1h_MCAo). The survival rate was 33% for the 
LV_shRNA_CyclinD1, 55% for the IDLV_TTC and 70% for the 
IDLV_GDNF.  
 
The comparison between the LV_shRNA_CyclinD1and the IDLV_GDNF 
by the Gehan-Breslow-Wilcoxon Test, demonstrated significant difference 
survival proportion between groups, *p<0.05, (Figure 6.f28). 
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Figure 6.f28. Survival proportion. 
 
Treatments affect survival proportion: 33% for the LV_shRNA_Cyclin D1 group, 
70% the IDLV_GDNF, 55% the IDLV_TTC and 40% the LV_shRNA_Empty 
group. The curves were analysed in pair by the Gehan-Breslow-Wilcoxon Test; 
there was significant different survival fraction between the IDLV_GDNF and 
the LV_shRNA_Cyclin D1 treated groups, *p<0.05. 
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6.4.9 TREATMENTS ALTERING THE SURVIVAL 
EXPECTANCY 
 
The survival expectancy is the probability of surviving with a defined 
ischemic status. For instance, for an extremely severe stroke (for instance a 
20 score by the 0-28 focal deficit test), it is very unlikely that survival will 
last for more than 36 hours. In other words there is a negative correlation 
between the ischemia severity and life expectancy.  
 
This analysis was performed by associating the ischemic severity, 
behaviourally assessed at day 212 post stroke, with the number of days the 
animals survived post-surgery. The modulation of the SVZ neurogenesis 
by LVs and IDLVs affected the life expectancy in MCAo animals. A 
**p<0.01 and a ρ=-0.84 was associated to the control group; this means 
there is a negative correlation between the ischemia severity and life 
expectancy. Animals treated with the LV_shRNA_CyclinD1 showed a 
stronger correlation with ***p<0.001 and ρ=-0.928.  On the other hand the 
treatment with the growth factors reduced this negative correlation: 
IDLV_GDNF was *p<0.05 with ρ=-0.644 and the IDLV_TTC was 
*p<0.05 with ρ=-0.732, Spearman’s rank Correlation Coefficient (Figure 
6.f29).  
 
 
 
 
 
 
 
                                                
12 Day 2 was selected because generally it was the day the animals presented the highest sickness 
score, in terms of behaviour and frequency of death. After day 2 they tended to start the 
recovery. 
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Figure 6.f29. Life expectancy 
 
Spearman’s rank Correlation Coefficient between the neurological phenotype, 
estimated by the 0-28 focal deficit test at day 2, and the number of days the 
animal survived post ischemia. There was a statistically significant correlation 
between the ischemia severity and the number of days the subjects survived after 
1h_MCAo; for the LV_shRNA_Empty treated group, **p<0.01 and ρ13=-0.84. 
The modulation of the SVZ neurogenesis by LVs and IDLVs affected this 
correlation. The LV_shRNA_CyclinD1 was ***p<0.001 and ρ=-0.928, the 
IDLV_GDNF was *p<0.05 and ρ =-0.644 while the IDLV_TTC was *p<0.05 
and ρ =-0.732. LV_shRNA_Empty group n=10, IDLV_GDNF n=10, IDLV_TTC 
n=9 and LV_shRNA_CyclinD1 n=9. 
 
 
 
                                                
13 . The ρ value quantifies the direction and magnitude of the correlation  
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6.4.10 SPEARMAN’S RANK CORRELATION 
COEFFICIENT BETWEEN THE BEHAVIOUR SCORE AT 
DAY 30 AND THE ISCHEMIC VOLUME ESTIMATION 
 
The Spearman’s rank correlation coefficient analysis was performed 
between the score assigned to the animals the last day they were alive and 
the related ischemic volume. As shown by Figure 6.f30 there is a positive 
correlation between the two variables, *p<0.05 with ρ=0.5.  
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Figure 6.f30. Evaluation of the analysis: correlation between the 
behavioural score at day 30 and the ischemic volume quantification. 
 
The correlation between the behavioural phenotype assessed by the 0-28 focal 
deficit test and the ischemic volume quantification was performed by the 
Spearman’s rank Correlation Coefficient.  There is a significant correlation 
between the parameters analysed, *p<-0.05 with ρ=0.5.  
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6.4.11 CONCLUSION 
 
The injections of LVs and IDLVs in the SVZ were efficient tools to 
detect and monitor NPCs in the ischemic brain over a long time period (up 
to 30 days) (Figure 6.f1 to Figure 6.f9). 
 
Suppression of Cyclin D1 by the LV_shRNA_CyclinD1 efficiently 
inhibited neurogenesis of the SVZ as demonstrated by the low numbers of 
eGFP positive cells in the OBs and in the ipsilateral region (Figure 6.f2 
and Figure 6.f5). The number of eGFP-positive cells in the ischemic 
regions was significantly lower than in the control injected with empty 
vector, **p<0.01 by the Student’s test (Figure 6.f14). 
 
The eGFP positive cells were mainly found in the aca, CPu, cortex   
and corpus callosum (Figure 6.f2, 6.f6, 6.f7 and 6.f8). The maximum 
distance SVZ-derived cells were found from the SVZ was 1.17 mm in 
striatum (Figure 6.f6) and in the cortex was 1.87 mm (Figure 6.f7). 
 
Groups of eGFP positive cells like neurogenic islands were found in the 
cortex and striatum (Figure 6.f6 and Figure 6.f7). 
 
EGFP positive cells were found in the ipsilateral aca (Figure 6.f5). 
Moreover, the SVZ expansion was positive for DCX and eGFP and it was 
extended to the aca in the ispilateral but not the contralateral hemisphere; 
this suggests a possible radial migratory pathway for the NPCs (Figure 
6.f9) (Gotts and Chesselet 2005). 
 
The inhibition of neurogenesis in the SVZ by LV_shRNA_CylinD1 
did not alter the recovery of body weight or behavioural function after the 
intracranial injections, but delayed the restoration of the pre-ischemic 
weight after 1h_MCAo (Figure 6.f22). Moreover, the neurological 
improvement was statistically lower than the control and growth factors 
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treated groups, *p<0.05, Mann-Whitney rank sum test (Figure 6.f20). The 
“SVZ neurogenesis inhibition group” (i.e. CyclinD1-suppressed) 
drastically reduced its number of animals that survived across the first 5 
days post 1h_MCAo (Figure 6.f21).  
 
IDLV_GDNF and IDLV_TTC injected in the wall of the lateral 
ventricles increased the number of the intermediate ischemic subjects 
surviving the experiment. These subjects were able to improve their initial 
neurological conditions, mostly evident during the first five days post 
stroke (Figure 6.f24 and Figure 6.f25).  
 
From a first analysis of the survivors after 30 days of reperfusion a 
paradoxical worsening of neurological recovery became apparent (Figure 
6.f23). This impoverishment was found statistically different to the 
control, respectively **p<0.01 for the IDLV_GDNF and ***p<0.001 for 
IDLV_TTC; analysis by the Mann-Whitney rank sum test. 
  
MCAo is a very efficient model of stroke although high variability of 
ischemia severity is intrinsic to the model itself. For instance in a group of 
MCAo animals produced under the same conditions, three subgroups 
based on the damage severity and location can be recognised: the mild, the 
intermediate and the severe ischemic group.  Each of these responds 
differently in terms of survival ability and post operation recovery. In this 
experiment the modulation of the SVZ strongly affected the ability of the 
subgroups to respond to ischemia, by means the IDLV_GDNF increased 
life expectancy for the intermediate ischemic subgroup and improved 
conditions in the mild animals. The comparison with the control group, 
which lost all the intermediate and severe subjects during the first ten days 
post operation, resulted in a misleading data analysis by which the 
treatment with growth factors looked to reduce the neurological recovery. 
Some laboratories avoid complications like this by a selections of the 
subjects based on the location and the damage size severity (Smith, 
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Stroemer et al.). In this project, due to the limited number of animals 
available, a proper selection of the subjects with similar ischemic 
characteristics was not possible as it would lead to insufficient statistical 
power. For this reason an analysis of the first five days post-surgery was 
performed in order to have more subjects to compare with similar features 
(Figure 6.f24 and Figure 6.f25).  
 
The analysis of the animals that survived up to day 5 after MCAo and 
treated with LV_GDNF, showed a reduced ischemic phenotype (p=0.065) 
(Figure 6.f24).   
 
Accordingly the number of survivors with an intermediate severe 
lesion, and therefore a delay of the reduction of the inflammation process 
and brain restoration, the IDLV_GDNF as well as the IDLV_TTC injected 
groups presented a statistically significant increase of the inflammation 
volume,*p<0.05, Student’s t test (Figure 6.f10).  
 
Because the LV_shRNA_CyclinD1 lost many subjects with an 
intermediate severe lesion already during the first 5 days after MCAo, 
while the control group still had subjects with an equivalent damage at the 
same time point, the comparison between these two groups at early stage 
was considered misleading, since compared groups with different stroke 
severity and for this reason was not introduced in this manuscript. The 
analysis of the survivors after 30 days post MCAo resulted in more 
balanced conclusion because it only included milder subjects in both 
groups. 
 
The treatments differed in the survival proportion. Comparing to the 
control group that had a survival rate of 40%, the SVZ neurogenesis 
inhibition group (LV_shRNA_CyclinD1 injected) had only 33%, the 
neurogenesis augmented group (IDLV_GDNF) had 70% and the 
IDLV_TTC ended the experiment with 55% of subjects surviving. A 
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comparison between the effect of IDLV_GDNF and LV_shRNA_CycinD1 
showed there was a significant trend to increase or decrease (respectively) 
survival rate depending on how the neurogenesis of the SVZ responded, 
*p<0.05  (Figure 6.f28).  
 
The modulation of the SVZ produced variation in the animal’s life 
expectancy. The severity of the ischemia was negatively correlated with 
the number of days the subject survived after the injury, as the Spearman’s 
rank correlation coefficient proved for the LV_shRNA_Empty, **p<0.01 
with ρ=-0.86. The negative correlation can change in magnitude depending 
on the modulation of the progenitors proliferation in the SVZ; the 
neurogenesis boosting by IDLV_GDNF reduced the negative correlation 
with *p<0.05 and ρ= -0.644, while the LV_shRNA_CyclinD1 increased it 
with ***p<0.001 and ρ=-0.928. IDLV_TTC also reduced the negative 
correlation with *p<0.05 and ρ=-0.732 (Figure 6.f29).    
 
IDLV_GDNF injection close to the wall of the SVZ improved the 
natural response of neurogenesis to ischemia. The hypothesis that there is 
a positive linear correlation between the lesion severity and the ability of 
the SVZ to respond to ischemia was evaluated by a linear regression. 
Although it was not possible to assess a significant correlation between 
these variables in the control group, a strong correlation was statistically 
significant in the IDLV_GDNF treated group, *p<0.05 with R=0.68 by 
linear regression analysis (Figure 6.f18). Further studies on the correlation 
between the number of eGFP cells and the neurodegeneration volume 
demonstrated a strong relationship with ***p<0.001 and R=0.92; no 
correlation was found between the number green cells and the volume of 
glial scar, nor between the number of green cells and the volume occupied 
by activated  microglia (Figure 6.f19). 
 
The analysis of the body weight variation did not highlight any 
difference after the intracranial injections, even though the IDLV_TTC 
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treated group tended to have a reduced body weight already at this stage 
(part a) of Figures 6.f22 and 6.f27).  The neurogenesis boosting and 
inhibiting groups showed a trend to reduce the body weight recovery 
comparing to the control, this was particularly evident during the first 
week after MCAo. The group treated with the LV_shRNA_Cyclin D1 
presented a statistically significant reduced body weight at day 3 after 
1h_MCAo (part c) of Figure 6.f22), for which *p<0.05 was estimated by 
the Student’s t test. In addition, the animals treated with the IDLV_GDNF 
reduced the body weight at day 3 and 4 after 1h_MCAo, for which 
**p<0.01 was assigned by the Student’s t test (part d) and e) of Figure 
6.f27).   
 
The histology and behavioural analysis was validated by the 
Spearman’s rank Correlation Coefficient, which demonstrated a 
statistically significant data correlation, *p<0.05 with ρ=0.5 (Figure 6.f30). 
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189 
 
7.1 DISCUSSION 
 
Neurogenesis occurs in physiological as well as pathological 
conditions and it has been demonstrated in rodents and mammals  
(Bovetti, Gribaudo et al.; Wang, Zhang et al.; Lennington, Yang et al. 
2003; Yamashita, Ninomiya et al. 2006). Although in physiological 
conditions the role of neurogenesis has mostly been clarified (Whitman 
and Greer 2009; Shruster, Melamed et al. 2010; Yoshizaki and Osumi 
2010), in pathological conditions, for example after stroke, it is still not 
completely understood.  
 
Neurogenesis occurs post ischemia, but the newly-generated neurons tend 
to die during the first two weeks after injury (Lindvall and Kokaia 2004). 
Moreover, the production of glial cell types from SVZ progenitors is also 
possible (Voigt 1989; Zhang, Zhang et al. 2004; Menn, Garcia-Verdugo et 
al. 2006)  
 
Determining the role of neurogenesis in the SVZ would allow a better 
understanding of the brain’s functions and help to guide possible 
therapeutic strategies to improve stroke patients’ conditions. Motivated by 
these reasons this project intended to compare the effect of positive and 
negative modulation of SVZ neurogenesis on the outcome following focal 
brain ischemia. 
 
The first achievement of this study was the production of an efficient 
cell cycle inhibitor system based on LVs, which was designed to be used in 
vivo to block proliferation of the SVZ progenitors. The system was centred 
on the inactivation of the Cyclin D1 protein, which is a vital participant in 
G1 phase of the cell cycle; the inhibition of the Cyclin D1 activity is 
responsible for to the cell cycle arrest (Fu, Wang et al. 2004; Lange and 
Yee 2011). 
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The first method tested was a dominant negative isoform of Cyclin D1 that 
was cloned into a third generation Lentiviral backbone, and packed into 
LVs. This strategy was not successful, possibly due to two unexpected 
extra mutations in the dominant negative Cyclin D1. The results from the 
in vitro studies did not show any convincing effect of the LV_dnCyclinD1 
on the NIH3t3 cell, evaluated by Western Blot and MTT cell viability 
assay. 
 
The second strategy adopted was based on a shRNA directed against the 
Cyclin D1 mRNA, originally cloned into a second generation Lentiviral 
backbone by Thermo Scientific and packed in LVs. This G1 blocking 
system was validated in vitro by Western Blot analysis and MTT cell 
viability assay. Both investigations in agreement showed down regulation 
of the target protein and an efficient effect on cell proliferation and 
apoptosis.   
 
The mouse MCAo model was evaluated by different occlusion times 
in order to achieve an optimal ischemic model for long-term study. These 
experiments were important to allow the best model selection and to 
optimize post-operative care strategies. As described by Modo et al. 
(2000), animal care after the ischemia is crucial for the achievement of a 
successful experiment (Modo, Stroemer et al. 2000); MCAo is a very 
invasive procedure that needs some careful post-operative care in order to 
maximize life expectancy. On the other hand the analysis of the occlusion 
time was pivotal to establish which model was the best in terms of high 
survival rate with sufficient ischemic damage.  
 
The MCAo is a very well established model, and has been in use since 
1975 (Robinson, Shoemaker et al. 1975). One of the major issues with the 
model is the reproducibility of the infarct incidence and the lesion severity 
(Bederson, Pitts et al. 1986). There have been many studies focused on 
developing tools to recognize the source of variability, and in turn modify 
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the experimental procedure to improve the model. In 1986 Bederson et al. 
tried to address the problem by looking at variation of cannula insertion in 
relation to the damage produced. They recognized that uniform severe 
infarction only occurred when the MCA was occluded from its origin to 
the junction with the inferior cerebral vein. When the occlusion started at 2 
mm proximal to the MCA origin, the uniformity of the damage in the 
group was already compromised (Bederson, Pitts et al. 1986). The Middle 
cerebral artery in the rodent is located on the surface of the olfactory tract; 
from this first tract multiple branches originate and diverge to supply blood 
to different brain regions. For example, the medial perforating and the 
leticulo-striate originate between the beginning of the MCA and the lateral 
edge of the olfactory tract; these branches provide blood to the posterior 
part of the caudate-putamen complex. Conversely the anterior part of the 
caudate-putamen complex receives blood from the lateral striated branches 
originating from the MCA and from the Hubner’s arteries that originate 
from the anterior cerebral artery (ACA) (Tamura, Graham et al. 1981). 
 
Considering the entry site for the cannula at the carotid artery level, the 
surgery is considered performed once the cannula reaches the beginning of 
the MCA at the level of the olfactory tract; a proper blockage at this point 
ensures that all branches are blocked as well. Although all surgeries are 
performed in the same way, and the cannula is held in place by a suture on 
the main carotid artery (close to the entry site), movements are still 
possible (for example due to a convulsion or animal rotation) and these can 
be responsible for sliding the cannula down from the original site.  
 
Although the two models investigated, the pMCAo and the tMCAo, are 
both considered highly variable, in the temporary occlusion the restoration 
of blood flow is responsible for augmenting the cerebral damage and 
introducing variability. The cerebral flux restoration or reperfusion, can 
produce physical (due to the effect of the restored flux high pressure on the 
cerebral tissue) and chemical (oxidative stress, ROS production from 
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mitochondria) damage (Jung, Kim et al. 2010). Each tMCAo animal can 
experience a completely different damage induced by reperfusion; this can 
be dependent on the pressure of the restored flux as well as the oxidative 
stress and the amount of the ROS can vary. These parameters are subject-
specific and are very likely responsible for the increased variability 
observed in the temporary occlusion model (Heiss 1987; Badruddin, Taqi 
et al. 2011) 
 
In this study the major concern regarding the permanent occlusion was the 
extremely high incidence of death observed during the first 36 hours. In 
addition, a proper recovery was not observed for the surviving subjects. 
Since this project originated with the intention of understanding the 
possible relationship between SVZ neurogenesis and recovery, we 
concluded that the temporary occlusion model (1 hour of occlusion) was 
the most suitable in terms of ischemic phenotype, long-term survival and 
recovery capability.  
 
The neurogenesis augmentation systems were based on IDLV 
encoding for a precursor GDNF or a TTC cassette. In previous 
experiments Dr. Ahmed, who produced these transfer plasmids, 
demonstrated the in vitro effectiveness for both systems. 
 
The use of the IDLVs to deliver either the GDNF or the TTC cassette, was 
driven by the needs to assess the effect of the SVZ neurogenesis rather 
than the effect of the growth factors on the ischemic areas. Since the IDLV 
does not integrate into the host genome, in mitotically active populations, 
such as the SVZ neurogenic islands, the vector should be diluted out 
through sequential cell divisions (Wanisch and Yanez-Munoz 2009). In 
addition, the progenitor cells that originate in the SVZ leave the 
neurogenic area to reach the ischemic boundaries. In such circumstances 
the IDLVs containing the growth factors GDNF or TTC should remained 
localized, and are supposed to promote proliferation only surrounding the 
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injection site. The LV carrying the eGFP cassette was co-injected with the 
IDLVs, integrates the viral DNA into the host genome and is retained 
through cellular proliferation. For this reason eGFP is detectable not just 
surrounding the injection sites, but also in the migrated population found 
in the ischemic regions and the OBs.  
 
          In order to prove the effect of the neurogenesis modulator systems 
based on LVs and IDLVs in vivo, normal c57/bl6 mice were injected at the 
beginning of the RMS. Three weeks later the animals were killed to detect 
and quantify NPCs migrated at OBs level; technique reported by 
Goncalves et al. 2007. 
 
Many laboratories have attested that GDNF improves post-ischemic 
recovery; it was widely applied to improve stem cell transplantation 
(Chen, Gao et al. 2009; Lee, Park et al. 2009; Shen, Li et al. 2010), to 
stimulate SVZ neurogenesis by intra-cerebral infusion (Dempsey, Sailor et 
al. 2003; Kobayashi, Ahlenius et al. 2006), and to reduce edema and 
infarct size (Abe 2003). All these studies proved an effect of the GNDF in 
ischemic condition, although a direct action on the NPCs multiplication 
was not yet proved. The treatment in absence of stroke demonstrated a 
direct effect of GDNF on the NPCs multiplication in ependymal layer, for 
which *p<0.05 was assigned (comparison to the control), analysis by the 
Student’s t test. 
 
The TTC fragment has been described as a factor involved in the 
relocation of exogenous GDNF and IGF-1 (mature isoform) to the 
extracellular space after translation, with the effect of improving survival 
of degenerating neurons in rodents (Larsen, Benn et al. 2006; Roux, Saint 
Cloment et al. 2006; Chian, Li et al. 2009; Li, Chian et al. 2009; Moreno-
Igoa, Calvo et al. 2012). In addition, it has been reported in an ALS mouse 
model to reduce the decline in hindlimb muscle innervation and in turn to 
delay the disease onset (Moreno-Igoa, Calvo et al. 2010). The purpose of 
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this study was to understand the possible applicability of the TTC fragment 
to stroke therapy. Although, due to the high variability it is not possible to 
completely exclude an augmentation of the SVZ neurogenesis after the 
TTC treatment and in absence of stroke, a significant effect was not 
statistically demonstrated. On the other hand, at least some of the subjects 
treated with the IDLV_TTC had a strong boost of the SVZ proliferation.  
 
The purpose of this study was to understand the importance of the 
endogenous neurogenesis occurring in stroke by inhibition of the NPCs 
cell cycle. Although some studies already attempted a similar investigation 
by localized irradiation of the SVZ cells (Lazarini, Mouthon et al. 2009; 
Achanta, Capilla-Gonzalez et al. 2012), this project has the merit to be the 
first achieved the sub-ependymal layer cell cycle inhibition by lentiviral 
vector. The advantage of this system is the specificity of the target by 
which only NPCs are affected by the treatment; only mitotic cells 
transcribed and transduce Cyclin D1 for the cell cycle regulation, ensuring 
no effect for the post-mitotic cells in the surrounding area. The injection at 
RMS level proved the strength of the cell cycle regulation by Cyclin D1; 
for instance the mRNA inhibition was able to almost completely inhibit 
NPCs multiplication, estimated by quantification of the migrated cells at 
OBs level, (***p<0.001, Student’s t test). 
 
         The neurogenesis modulation systems were used to assess the role of 
the SVZ proliferation on stroke recovery. In this study the vectors were co-
injected at SVZ level and the MCAo was performed fourteen days later. 
The animals’ behaviour was observed for one month to detect the influence 
of the treatments on recovery, and then an histological evaluation was 
performed in order to assess ischemia, and to detect in this area the neural 
progenitor cells SVZ derived. 
 
         The SVZ derived eGFP+ cells were found in the aci, aca, GrO, CPu, 
sensorimotor cortex, SVZ and corpus callosum. The maximum distance 
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from the SVZ, where the migrated eGFP expressing cells were found, was 
in the cortex, 1.87 mm away; this long migration was in agreement with 
preceding publications (Yamashita, Ninomiya et al. 2006; Zhang, 
LeTourneau et al. 2007; Kreuzberg, Kanov et al. 2010; Young, Brooks et 
al. 2011).  
 
In accordance with the literature, we recurrently found eGFP positive cells 
toward the aca (Gotts and Chesselet 2005).  Moreover as shown in Figure 
6.f9, the DCX positive cells migrating from the ependymal layer at the 
bottom of the third ventricle, to the aca ventrally localized, suggest a 
possible migratory pathway induced after ischemia. In agreement with 
previous publications, we hypothesized that at least some of the cells 
utilized the aca for migration, similarly with the migration occurring 
through the corpus callosum in the same conditions (Imitola, Raddassi et 
al. 2004; Gotts and Chesselet 2005). 
 
As described before, we found migrated cells in the cortex and striatum; 
moreover eGFP positive cells were localized across the corpus callosum 
and anterior commissure. It might be possible in addition to the radial 
migration; the NPCs use the commissure and the corpus callosum as “free 
way” to drive into the neuronal tissue and reach the ischemic environment.   
 
As Yamashita et al reported previously, some of the cells migrated from 
the SVZ were found in the ischemic cortex and striatum were spread 
through the tissue, while others were grouped-like neurogenic islands 
(Yamashita, Ninomiya et al. 2006). 
 
In agreement with previous in vivo and in vitro experiments, the LVs and 
IDLVs efficiently affected the SVZ progenitors multiplication; this was 
estimated based on the number of the eGFP positive cells migrated in the 
ischemic environment after ischemia. The animals pre-treated with 
LV_shRNA_CyclinD1 presented an extremely reduced number of eGFP 
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positive cells in the ischemic regions, for which **p<0.01was assigned. 
Conversely, a statistically significant increase of eGFP positive cells was 
estimated for the animals treated with IDLV_GDNF, *p<0.05.  The 
IDLV_TTC, as already reported in the previous in vivo experiment, 
showed an extremely high variability; in addition the low number of 
survivors (n=10, 5 survivors) did not allow any reliable estimation of the 
treatment effect. For these reasons and although the increased variability 
within the survival fraction, it was not possible to evaluate the effect of the 
treatment. These analyses were performed by the Student’s t test. 
 
In the IDLV_GDNF treated group the number of eGFP+ cells migrated 
into the ischemic regions after stroke was positively correlated with the 
damage volume, *p<0.05 with R=0.68, by linear regression analysis.  
Moreover, a further analysis between the eGFP+ cells and each specific 
component of the ischemic environment, revealed a strong correlation 
exclusively with the neurodegeneration fraction (core region), ***p<0.001 
and R=0.92, but not with the glial scar or the microglia covered volume. 
From the literature, it is known that SVZ proliferation is highly regulated 
by factors and compounds acting over long distances. This regulation 
occurs lifelong in physiological conditions; for example, the OBs induce 
multiplication and migration of the SVZ progenitors toward the RMS 
(Kazanis 2009). In a very similar way and in pathological conditions, for 
example after stroke or a traumatic brain injury (TBI), the SVZ progenitors 
are induced to multiply and migrate toward the lesion area (Kernie and 
Parent 2010; Luzzati, De Marchis et al. 2011).  It is also well known that 
the ischemic environment produces factors involved in controlling SVZ 
proliferation and migration (Salazar-Colocho, Lanciego et al. 2008; 
Whitney, Eidem et al. 2009; Yoneyama, Shiba et al. 2011). Since diverse 
cellular populations compose the ischemic environment, the data presented 
in this study support the hypothesis of a tight regulation of SVZ 
proliferation dependent on the core region (neurodegenerative area). It 
might be possible that, analogue to the activated astrocytes that produce 
 
 
197 
 
chemokine like SDS-1 to induce migration of the NPCs, the core region 
acts long distance on the ependymal cells proliferation (Hill, Hess et al. 
2004; Jaerve and Muller 2012; Wang, Huang et al. 2012). 
 
The pre-treatment of the SVZ with the IDLV_GDNF increase the 
survival rate while LV_shRNA_Cyclin D1 reduced it; the survival curves 
in these two groups were statistically different. Moreover, the life 
expectancy, defined as the ability to survive with a defined ischemic 
status, was increased when subjects were treated with IDLV_GDNF, as 
well as it decreased when the treatment was LV_shRNA_CyclinD1.         
 
Take in consideration the limited investigation power allowed by the 
selected behavioral test (0-28 focal deficit test), the groups were analyzed 
and compared using non-parametric statistic. MCAo animals previously 
injected with the LV_shRNA_CyclinD1 were compared to the control 
group for the sensorimotor phenotype. The analysis demonstrated a 
significant increase in the ischemic phenotype and delay of recovery 
evaluated by the Mann-Whitney rank sum test, *p<0.05. This analysis was 
performed on the fraction of survivors.  
 
MCAo animals previously injected with the IDLV_GDNF or IDLV_TTC 
and survived for thirty days after the ischemia were initially evaluated for 
the sensorimotor impoverishment. From this preliminary investigation, the 
groups treated with the growth factor and TTC had a significant reduction 
in the sensory-motor performance when compared to the control  
(**p<0.01 for IDLV_GDNF and ***p<0.001 for IDLV_TTC).   
Considering the survival rate (70% in the GDNF and 55% in the TTC 
versus 40% in the control) and the improvement of the life expectancy, but 
conversely the reduced post-operative body weight and the significant 
increase in inflammation volume, we hypothesize a selection agent 
affected the survival fraction in these groups. Despite the longer survival, 
these subjects were still highly ischemic, while the same sub-population in 
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the control group was already dead after the first week post MCAo. In 
these conditions the comparison between groups was highly unbalanced 
because attempted to compare subjects with different brain damage 
severity (and different location), which may have significantly skewed the 
results. Following on this, the animals that survived at least until day 5 
after ischemia were analysed for the sensorimotor behaviour. Under these 
circumstances, is our belief that both groups included a more heterogenic 
ischemic population with similar characteristics (as at this stage the 
intermediate severity subjects in the control group were still alive). The 
sensory-motor recovery for the survivors of the GDNF treated group that 
were alive up to day five, although did not prove a statistically significant 
improvement in comparison to the control group, showed a clear trend to 
recovery.  
 
        Although IDLV_GDNF improved animal healing, a complete 
recovery was not observed for all surviving subjects, especially the ones 
with severe ischemic damage. However, the rate of sensorimotor recovery 
varied, being proportional to the initial damage, and faster in IDLV_GDNF 
treated subjects. From the animals’ observation, it looks reasonable to 
postulate that the modulation of the SVZ affected mostly the ability to 
survive more than the motor recovery. In addition, and in agreement with 
the literature, the pre-treatment with GDNF reduced the severity of the 
ischemia within the group, highlighting a protective effect from ischemia 
onset and progression (Yu, Liu et al. 2007; Chu, Wang et al. 2008).  
 
The histological analysis did not show any sign of tissue re-building, 
which taken together with the disperse location of the migrated cells seems 
to suggest a different role of the NPCs in stroke. The data from the 
survival proportion, life expectancy and sensorimotor behaviour suggest 
the SVZ is an important factor involved in recovery. In addition the 
number of eGFP positive cells estimated in the ischemic boundaries was 
not big enough to justify such a large effect on animal survival. For these 
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reasons we cannot exclude a role of these cells on the animal healing 
process; it seems reasonable to postulate an indirect influence of the SVZ 
progenitors on the ischemic lesion. It might be the case that these cells are 
involved in brain restoration by producing growth factors in turn 
responsible to improve neuronal survival, and branching in the penumbra 
area.  
 
        Many studies are currently focused on brain repair by stem cells 
transplantation or improvement of the endogenous neurogenesis by growth 
factors therapy. Although some of them involving human and animal 
models demonstrated neurological improvement, the efficiency and 
potentiality of the treatment as well as the mechanism of action is still not 
clarified (Dibajnia and Morshead 2012; Maucksch, Vazey et al. 2012; 
Oliveira, Pillat et al. 2012; Sakata, Narasimhan et al. 2012; Song, 
Mohamad et al. 2012). One of the major issue of stem cells transplantation, 
is the engrafted cells survival, between 5 and 10% of the originally 
transplanted cells; this makes even more difficult to comprehend how the 
treatment could have any effect on the neurological outcome (Fainstein, 
Cohen et al. 2012; Mora-Lee, Sirerol-Piquer et al. 2012; Wang, Forsythe et 
al. 2012). Many of these researches failed to prove a proficient tissue re-
building, leaving open the doubt of a real effect of the treatment over the 
sometime weak proves for the neurological enhancement. Something to 
keep in mind and suggested from this thesis, is the possibility of a different 
action of the endogenous neurogenesis in the healing process. In addition, 
the functionality of the NPCs (endogenous and exogenous) might go over 
the “simple” tissue formation, and we might need to start looking at the 
phenomena under different light and prospective. 
 
The ability to repair by replacement is not necessary the only way for 
recovery, and if it is very efficient for the majority of the organs healing 
process, it might not applicable for the Nervous System. The Nervous 
System is matter of memories and connections built up in a lifetime, 
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repairing by replacement might not be the most efficient way to heal. The 
neurological significance of a neuron is not just the ability to receive input 
and release output, but the specificity of the connections and excitability is 
like a code that reflects the organism regulation. It is very possible that the 
system receives more benefit by enhancing plasticity rather than replacing 
dead neurons. Under this light an improvement of this study with a bigger 
number of subjects and a proper selection of the behavioural tests would 
better clarify the brain healing potentiality and open new strategies for 
brain restoration.  
 
 
7.2 TROUBLESHOOTING 
 
During the project development a number of issues rose up; in this session 
I will describe some of the problems met and trouble shutting.    
 
         The analysis in vitro of the LV_dnCyclinD1 did not clarify the 
effectiveness of the mutant. Although the cell cycle analysis was 
performed at different time points after transduction, the efficacy of the 
mutant was not proved or clarified.  The major issue with the experimental 
design used, was the absence of an inducible promoter to drive the 
dnCyclinD1 expression, combined with an antibiotic resistance gene for 
selection. These two modifications on the transfer plasmid would make 
possible the selection of an uniform population that is efficiently 
transduced, in addition to a better control of the transgene transcription at 
the desired time point. The predicted effect would be to reduce issues 
related on selection agents on the non-transduced fraction, over the portion 
that activates the mutant and reduce or block the cell cycle. The non-
transduced fraction will always have a faster or active cell cycle leading a 
time dependent amplification (the NIH3t3 doubling time is 2 days), in turn 
affecting protein and viability analysis of the whole system (transduced 
and non-transduced fraction). 
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 In vivo behavioural examination was limited by a not exhaustive test, 
only able to detect a portion of the damage produced by 1h_MCAo. The 
analysis of the sensorimotor phenotype was assessed based on the 0-28 
focal deficit test, which allows evaluation of damage located in the 
sensorimotor cortex and striatum. Because the lesion of many subjects 
extended to the hippocampus, the behavioural analysis performed was not 
sufficient to evaluate the whole effect of the ischemia, and perform a 
proper comparison. Although the MCAo model is known to induce 
damage to the striatum and sensorimotor cortex, as the literature reported, 
the most severe ischemic subjects can show damage extended also to the 
hippocampal formation and hypothalamus (Liu, Solway et al. 1998; 
Gerriets, Stolz et al. 2003; Nikonenko, Radenovic et al. 2009; Li, Pang et 
al. 2012). For a proper evaluation of the model, subject selection based on 
damage severity and location, in addition to proper behavioral tests is 
strongly recommended. Alternatively, the use of an heterogenic battery of 
tests needs to be performed. Considering these factors, the model could 
have been more exhaustively analyzed with further tests like the Morris 
water maze, the 8 arms radial maze or the t-maze (Hodges 1996; Sharma, 
Rakoczy et al. 2010; Nikbakht, Zarei et al. 2012).  
 
   Ultimately, the statistic power was very small due to the reduced 
size groups performed. The number of subjects used in an experiment 
depends on the survival fraction expected at the end of the treatment. In an 
animal study (especially when the behavior is evaluated) a minimum of 10-
15 subjects (survivors) is recommended. On the light of the survival 
fraction estimated by this project a minimum number of 30-32 animals per 
group would have been advisable (especially for the SVZ inhibition 
group).   
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